

CITATION REPORT

List of articles citing

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

DOI: 10.1016/j.bbmt.2005.09.004

Biology of Blood and Marrow Transplantation, 2005, 11, 945-56.

Source: <https://exaly.com/paper-pdf/39350177/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2323	Pathology of Hematopoietic Stem Cell Transplantation. 260-293		
2322	Dermatological Complications in Transplant Patients and Composite Tissue Allotransplant Pathology. 294-311		
2321	Standardizing chronic graft-versus-host disease. 2006 , 2, 459-62		3
2320	Chronic graft-versus-host disease: Pathogenesis and clinical management. 2006 , 66, 1041-57		59
2319	Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 31-47	4.7	357
2318	Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 252-66	4.7	344
2317	Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 275-84	4.7	287
2316	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 491-505	4.7	150
2315	Cutaneous manifestations of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1101-13	4.7	68
2314	The changing face of graft-versus-host disease. 2006 , 25, 190-200		36
2313	Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. 2006 , 108, 2867-73		214
2312	Update on ocular graft versus host disease. 2006 , 17, 344-8		71
2311	Chronic graft versus host disease. 2006 , 13, 426-35		93
2310	Review article: management of hepatic disease following haematopoietic cell transplant. 2006 , 24, 441-52		35
2309	Assessing the potential role of photopheresis in hematopoietic stem cell transplant. 2006 , 38, 265-73		55
2308	Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. 2006 , 38, 645-51		75
2307	Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. 2006 , 17, 1995-2005		112

2306 Chronic graft-versus-host disease. **2006**, 33, 881-3

2305 Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist. **2006**, 2, 369-379

7

2304 Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. **2007**, 41, 1436-44

20

2303 GVHD the nuts and bolts. **2007**, 2007, 62-7

38

2302 Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. **2007**, 110, 1041-9

59

2301 Bronchiolitis obliterans following haematopoietic stem cell transplantation. **2007**, 29, 1007-19

80

2300 Haematopoietic stem cell transplantation: can our genes predict clinical outcome?. **2007**, 9, 1-19

33

2299 How I treat refractory acute GVHD. **2007**, 109, 4119-26

343

2298 Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. **2007**, 109, 1756-64

117

2297 Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. **2007**, 110, 3804-13

185

2296 Progress in acute graft versus host disease. **2007**, 14, 625-31

6

2295 Montelukast in chronic graft-versus-host disease: a breath of fresh air?. **2007**, 83, 527-8

2

2294 Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. **2007**, 83, 577-81

35

2293 Current World Literature. **2007**, 18, 188-213

2292 Predominant infiltration of monocytes in chronic graft-versus-host disease. **2007**, 83, 220-4

12

2291 Approach to the acute, generalized, blistering patient. **2007**, 26, 139-46

12

2290 Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 299-306

4-7 70

2289 Transplantation's greatest challenges: advances in chronic graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 2-10

4-7 59

2288	Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 701-6	4-7	48
2287	A single-center pilot validation study of a new chronic GVHD skin scoring system. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 715-23	4-7	38
2286	Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1145-52	4-7	54
2285	Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1207-15	4-7	87
2284	Minimal change nephrotic syndrome after stem cell transplantation: a case report and literature review. 2007 , 1, 121		11
2283	Graft-versus-host disease: review and nursing implications. 2007 , 11, 325-8		15
2282	Liver Immunology. 2007 ,		4
2281	Prednisone plus a calcineurin inhibitor are considered standard treatment for chronic graft-versus-host disease, but the best regimen for salvage treatment is not clear. 2007 , 23, 7-10		
2280	Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. 2007 , 82, 45-52		130
2279	The effect of budesonide mouthwash on oral chronic graft versus host disease. 2007 , 82, 349-56		33
2278	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. 2007 , 82, 867-72		46
2277	Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. 2007 , 40, 465-72		26
2276	Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD. 2007 , 40, 779-84		6
2275	Chronic graft-versus-host disease in the era of reduced-intensity conditioning. 2007 , 21, 853-9		26
2274	Photopheresis in graft-vs.-host disease. 2007 , 2, 102-105		1
2273	Oral graft vs. host disease in children--treatment with topical tacrolimus ointment. 2007 , 11, 306-11		36
2272	The management and outcome of chronic graft-versus-host disease. 2007 , 138, 131-45		31
2271	Mucosal graft-vs-host disease. 2007 , 13, 519-29		17

2270	Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. 2007 , 27, 1627-36	144
2269	Graft-versus-Host-Erkrankung. 2007 , 155, 1021-1030	1
2268	The immunopathology of thymic GVHD. 2008 , 30, 439-56	56
2267	Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. 2008 , 41, 56-78	22
2266	Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. 2008 , 88, 575-582	7
2265	Graft rejection after hematopoietic cell transplantation with nonmyeloablative conditioning. 2008 , 83, 563-9	4
2264	Quantitative analysis of Langerhans' cells in oral chronic graft-vs.-host disease. 2009 , 38, 132-7	7
2263	Oral graft-versus-host disease. 2008 , 14, 396-412	89
2262	Immune modulation and chronic graft-versus-host disease. 2008 , 42 Suppl 1, S66-S69	34
2261	Immuno-hematopoietic stem cell transplantation: introduction and 35 years of development in South Africa--the historical and scientific perspective. 2008 , 42 Suppl 1, S125-S132	5
2260	Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT. 2008 , 42, 289-91	1
2259	Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. 2008 , 42, 541-6	12
2258	Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. 2008 , 42, 609-17	103
2257	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. 2008 , 41, 651-8	12
2256	Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. 2008 , 41, 729-36	5
2255	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. 2008 , 41, 887-93	17
2254	Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. 2008 , 6, 1468-73	52
2253	Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. 2008 , 10, 252-9	20

2252	Vascular endothelium and graft-versus-host disease. 2008 , 21, 129-38		64
2251	GVHD pathophysiology: is acute different from chronic?. 2008 , 21, 101-17		54
2250	Diagnosis and manifestations of chronic graft-versus-host disease. 2008 , 21, 251-7		81
2249	Prevention of chronic GVHD. 2008 , 21, 259-70		14
2248	Impact of graft-versus-host disease on survival. 2008 , 21, 193-204		43
2247	Ancillary and supportive care in chronic graft-versus-host disease. 2008 , 21, 291-307		25
2246	Late effects of chronic graft-versus-host disease. 2008 , 21, 309-31		19
2245	Study design and endpoints in graft-versus-host disease. 2008 , 21, 357-72		19
2244	Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models. 2008 , 27, 74		12
2243	Rippled skin, fasciitis, and joint contractures. 2008 , 59, 1070-4		6
2242	Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports. 2008 , 106, e11-7		12
2241	Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 10-5	4-7	63
2240	Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 208-19	4-7	94
2239	Late effects following hematopoietic cell transplantation for children. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 88-93	4-7	12
2238	Chronic graft-versus-host disease: how can we release Prometheus?. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 142-50	4-7	17
2237	Murine models of chronic graft-versus-host disease: insights and unresolved issues. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 365-78	4-7	110
2236	Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 379-84	4-7	17
2235	Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 426-37	4-7	11

2234	Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 531-7	4-7	42
2233	Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1108-1117	4-7	61
2232	Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1125-1133	4-7	43
2231	Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1163-1171	4-7	72
2230	Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1380-4	4-7	38
2229	Oral graft-versus-host disease. 2008 , 52, 79-109, viii-ix		103
2228	Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. 2008 , 8, 161-79		15
2227	Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. 2008 , 17, 1389-401		3
2226	Comparison of infantile hemangiomas in preterm and term infants: a prospective study. 2008 , 144, 1231-2		37
2225	Recognizing and managing chronic graft-versus-host disease. 2008 , 134-41		145
2224	Graft-versus-host disease and immunologic rejection: implications for diagnosis and treatments of pregnancy complications. 2008 , 3, 37-49		7
2223	Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. 2008 , 125-33		47
2222	Spatial distribution of histone isoforms on the bovine active and inactive X chromosomes. 2008 , 2, 12-23		18
2221	Safety of hematopoietic stem cell transplantation in children less than three years of age. 2008 , 25, 705-22		10
2220	Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. 2008 , 26, 577-84		173
2219	Cutaneous graft-versus-host disease: a guide for the dermatologist. 2008 , 216, 287-304		81
2218	Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. 2008 , 112, 2579-82		37
2217	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. 2008 , 111, 5530-6		261

2216	Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. 2008 , 112, 2979-89	213
2215	Non-infectious bronchiolitis as an early pulmonary complication of hematopoietic stem cell transplantation. 2008 , 47, 61-4	2
2214	Chronic graft-versus-host disease. 2008 , 14, 1974-86	11
2213	The use of growth factors in hematopoietic stem cell transplantation. 2008 , 14, 1950-61	53
2212	Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. 2008 , 86, 875-9	46
2211	?4? GVHD?????????????????. 2008 , 15, 9-26	
2210	B-cell involvement in chronic graft-versus-host disease. 2008 , 93, 1702-11	46
2209	Current and future approaches for control of graft-versus-host disease. 2008 , 1, 111	23
2208	High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. 2008 , 23, 244-50	58
2207	Hematopoietic stem cell transplantation for malignant diseases. 2008 , 1223-1236	
2206	The Strategies for the Prevention of Chronic GVHD in Hematopoietic Stem Cell Transplantation. 2008 , 43, 1	1
2205	The isomorphic response in morphealike chronic graft-vs-host disease. 2008 , 144, 1229-31	14
2204	Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. 2008 , 57, 177-83	42
2203	Effect of Etanercept on Steroid Refractory Graft-versus-host Disease in Children. 2009 , 44, 212	
2202	Diagnosis and treatment of graft-versus-host-disease. 331-356	
2201	Graft-Versus-Host Disease [Chronic. 76-97	
2200	Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. 2009 , 4, e6203	37
2199	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. 2009 , 50, 1809-17	47

2198	Emerging drugs for acute graft-versus-host disease. 2009 , 14, 219-32	3
2197	Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation. 2009 , 207, E17; discussion 428-9	24
2196	A call for more dermatologic input into chronic graft-vs-host disease clinical trials. 2009 , 145, 337-8	1
2195	Multiple morphea-like lesions associated with chronic graft-versus-host disease after cord blood transplantation. 2009 , 89, 86-7	5
2194	Acute graft-versus-host disease. 2009 , 387-400	3
2193	Chronic graft-versus-host disease. 2009 , 401-407	4
2192	Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. 2009 , 302, 306-14	149
2191	High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. 2009 , 83, 357-64	23
2190	First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. 2009 , 133, 22-6	477
2189	Hämatopoetische Stammzelltransplantation. 2009 , 15, 564-574	
2188	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. 2009 , 90, 253-260	43
2187	Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. 2009 , 146, 310-6	80
2186	Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. 2009 , 157, 104-18	255
2185	Tear function and lipid layer alterations in dry eye patients with chronic graft-vs-host disease. 2009 , 23, 202-8	16
2184	Feasibility of NIH consensus criteria for chronic graft-versus-host disease. 2009 , 23, 78-84	91
2183	The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. 2009 , 23, 1-2	7
2182	Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. 2009 , 43, 159-67	40
2181	New classification of chronic GVHD: added clarity from the consensus diagnoses. 2009 , 43, 149-53	78

2180	Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. 2009 , 43, 477-80		10
2179	Long-term survival after HLA-haploidentical SCT from noninherited maternal antigen-mismatched family donors: impact of chronic GVHD. 2009 , 44, 327-9		15
2178	Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. 2009 , 44, 393-403		19
2177	Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. 2009 , 44, 601-5		30
2176	Chronic GVHD manifesting as parotitis after allogeneic hematopoietic SCT. 2009 , 44, 821-2		3
2175	Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. 2009 , 44, 805-12		11
2174	Bronchiolitis obliterans following hematopoietic stem cell transplantation: a clinical update. 2010 , 24, 291-306		17
2173	Isomorphic disposition of chronic graft-versus-host disease in striae distensae. 2009 , 23, 574-5		10
2172	Generalized melanosis caused by an occult melanoma. 2009 , 23, 575-7		2
2171	NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. 2009 , 81, 9454-61		10
2170	Diagnostic approach of pulmonary disease in the HIV negative immunocompromised host. 2009 , 20, 268-79		6
2169	Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 61-72	4-7	22
2168	Improving hematopoietic cell transplant outcomes in a new era of genomic research. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 42-5	4-7	12
2167	Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 336-43	4-7	21
2166	Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 370-6	4-7	48
2165	Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, e1-7	4-7	4
2164	Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 416-20	4-7	12
2163	Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 471-82	4-7	20

2162	Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 554-63	4-7	31
2161	Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 671-8	4-7	32
2160	Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 777-84	4-7	52
2159	Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 910-8	4-7	42
2158	Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1005-13	4-7	101
2157	Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 919-29	4-7	33
2156	Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 948-55	4-7	27
2155	Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1122-9	4-7	48
2154	Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1251-7	4-7	46
2153	Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1331-6	4-7	11
2152	Infliximab for managing steroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1116-21	4-7	24
2151	Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1288-95	4-7	55
2150	Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1314-22	4-7	25
2149	Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1502-12	4-7	20
2148	Survivorship issues in hematopoietic stem cell transplantation. 2009 , 25, 159-69		7
2147	History of hematopoietic stem cell transplantation. 2009 , 25, 95-9		12
2146	Advances in hematologic stem cell transplant: an update for oral health care providers. 2009 , 107, 301-12		43
2145	Ocular findings after allogeneic hematopoietic stem cell transplantation. 2009 , 116, 1624-9		102

2144	Pathology of graft-versus-host disease in the gastrointestinal tract. 2009 , 40, 909-17		192
2143	Principles and overview of allogeneic hematopoietic stem cell transplantation. 2009 , 144, 1-21		14
2142	The Pathophysiology of Graft-Versus-Host Disease. 208-221		2
2141	Late complications after hematopoietic stem cell transplantation. 2009 , 2, 583-601		57
2140	Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 881-5	4-7	34
2139	Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease. 2009 , 175, 2372-81		48
2138	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. 2009 , 10, 855-64		497
2137	Graft-versus-host disease. 2009 , 373, 1550-61		1698
2136	Clinical significance of autoantibody expression in allogeneic stem-cell recipients. 2009 , 88, 242-50		10
2135	Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. 2009 , 21 Suppl 1, S35-7		6
2134	Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. 2009 , 21 Suppl 1, S39-41		10
2133	Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. 2009 , 88, 1261-72		99
2132	Hematopoietic Progenitor Cells: Allogeneic Transplantation. 542-558		
2131	Specialized Therapeutic Hemapheresis and Phlebotomy. 652-680		
2130	Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. 2009 , 113, 3620-30		86
2129	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. 2009 , 113, 4144-52		165
2128	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. 2009 , 113, 5074-82		120
2127	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. 2009 , 114, 702-8		187

2126	Magic bullet, part III?. 2009 , 114, 498-9	1
2125	Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. 2009 , 114, 744-6	38
2124	Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. 2009 , 114, 4354-60	39
2123	The role of B cells in the pathogenesis of graft-versus-host disease. 2009 , 114, 4919-27	207
2122	Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. 2009 , 145, 918-22	13
2121	Dermatologic manifestations of hematopoietic stem cell transplantation: understanding and management. 2009 , 4, 637-654	2
2120	Pathophysiology of Chronic Graft versus Host Disease. 17-30	6
2119	Incidence and Trends. 46-55	1
2118	Clinical Manifestations and Natural History. 56-69	4
2117	Animal Models of Chronic Graft versus Host Disease. 31-45	1
2116	Risk Factors and Predictive Models for Chronic Graft versus Host Disease. 70-78	
2115	Diagnosis and Staging. 87-100	2
2114	Prevention of Chronic Graft versus Host Disease. 117-123	1
2113	Front Line Treatment of Chronic Graft versus Host Disease. 124-133	6
2112	Evaluating Therapeutic Response in Chronic Graft versus Host Disease. 146-156	
2111	General Principles of Ancillary and Supportive Care. 157-166	1
2110	Cutaneous Manifestations of Chronic Graft versus Host Disease. 169-181	2
2109	Oral Chronic Graft versus Host Disease. 182-198	2

2108	Chronic Ocular Graft versus Host Disease. 199-206	7
2107	Gynecological Manifestations of Chronic Graft versus Host Disease. 207-215	1
2106	Chronic Graft versus Host Disease and the Lung. 229-237	1
2105	Spectrum of Chronic Graft versus Host Disease in Unique Clinical Situations: The Role of Stem-Cell Source Including Cord Blood Stem Cells, Reduced-Intensity Conditioning, and Donor Leukocyte Infusions. 360-368	
2104	Pediatric Chronic Graft versus Host Disease. 369-385	1
2103	Principles of Interdisciplinary Practice in the Care of Patients with Chronic Graft versus Host Disease. 386-395	2
2102	Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. 2009 , 15, 1974-97	29
2101	Analysis of memory and effector CD8+ T cell subsets in chronic graft-versus-host disease. 2009 , 22, 195-205	5
2100	Musculocutaneous chronic graft-versus-host disease: MRI follow-up of patients undergoing immunosuppressive therapy. 2009 , 192, 1401-6	4
2099	Current insights into ocular graft-versus-host disease. 2010 , 21, 485-94	55
2098	Allogreffe de cellules souches h�matopo�iques : r�alisation et complications. 2010 , 5, 1-19	
2097	[Non-infectious pulmonary complications after the hematopoietic stem cell transplantation]. 2010 , 16, 815-28	
2096	Immune processes and pathogenic fibrosis in ocular chronic graft-versus-host disease and clinical manifestations after allogeneic hematopoietic stem cell transplantation. 2010 , 29 Suppl 1, S68-77	15
2095	Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides. 2010 , 90, 555-63	3
2094	Effects of pravastatin on murine chronic graft-versus-host disease. 2010 , 90, 853-60	19
2093	Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD. 2010 , 32, 589-93	21
2092	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. 2010 , 95, 1176-82	61
2091	Ocular graft-versus-host disease after allogeneic stem cell transplantation. 2010 , 29, 758-63	90

2090	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. 2010 , 115, 3224-30	281
2089	Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. 2010 , 116, 4859-69	35
2088	Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. 2010 , 45, 912-8	3
2087	Clinical-pathological conference: case 2. 2010 , 4, 221-5	2
2086	Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. 2010 , 91, 436-45	14
2085	Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. 2010 , 92, 342-50	18
2084	Genital manifestation of graft-vs.-host disease: a series of case reports. 2010 , 7, 3216-25	14
2083	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. 2010 , 116, 3631-7	20
2082	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. 2010 , 85, 290-3	1
2081	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. 2010 , 85, 288-90	50
2080	Is the JAK2(V617F) mutation detectable in healthy volunteers?. 2010 , 85, 287-8	28
2079	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: a multicenter case finding study in Spain. 2010 , 85, 294-6	4
2078	Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. 2010 , 85, 296-9	
2077	Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions. 2010 , 85, 300-1	1
2076	ASH 2009 meeting report—top 10 clinically oriented abstracts in acute leukemia. 2010 , 85, 277-280	0
2075	ASH 2009 meeting report—top 10 clinically oriented abstracts in lymphoma. 2010 , 85, 280-283	
2074	ASH 2009 meeting report—top 10 clinically oriented abstracts in chronic myeloid leukemia. 2010 , 85, 283-286	0
2073	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. 2010 , 50, 2424-31	19

2072	Basement membrane antibodies in sera of haematopoietic cell recipients are associated with graft-versus-host disease. 2010 , 24, 587-94	11
2071	Clinicopathologic characteristics of cutaneous chronic graft-versus-host diseases: a retrospective study in Korean patients. 2010 , 49, 1386-92	20
2070	Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. 2010 , 162, 404-9	32
2069	Optimal management of chronic graft-versus-host disease in children. 2010 , 150, 278-92	29
2068	Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. 2010 , 24, 1276-82	81
2067	The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. 2010 , 24, 1852-8	49
2066	Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. 2010 , 24, 1236-9	22
2065	Eosinophilia predicts better overall survival after acute graft-versus-host-disease. 2010 , 45, 371-7	18
2064	Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. 2010 , 45, 565-9	37
2063	Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). 2010 , 45, 762-9	75
2062	Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. 2010 , 45, 1732-40	186
2061	Many faces of graft-versus-host disease. 2010 , 51, 1-10; quiz 11	41
2060	Outcome of hematopoietic stem cell transplantation of children with very high risk acute lymphoblastic leukemia in first complete remission. 2010 , 14, 377-82	1
2059	Bone Marrow Transplantation. 2010 , 198-210	
2058	The role of photopheresis in the treatment of graft-versus-host disease. 2010 , 17, 55-8	24
2057	Hematopoietic stem cell transplantation. 2010 , 3, 105-17	44
2056	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. 2010 , 28, 2859-67	163
2055	Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. 2010 , 95, 1935-42	78

2054	Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. 2010 , 19, 333-40	24
2053	Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. 2010 , 45, 1077-83	58
2052	Glomerular lesion and increased cytokine gene expression in renal tissue in patients with decompensated nephrotic syndrome due to chronic GvHD. 2010 , 32, 510-4	11
2051	Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. 2010 , 28, 1878-87	385
2050	Clinical Aspects Of Sclerodermatous Type Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 2010 , 27, 91-8	3
2049	Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. 2010 , 45, 1062-7	24
2048	Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. 2010 , 45, 1038-46	97
2047	Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. 2010 , 45, 1347-51	59
2046	Differential chemokine expression in chronic GVHD of the conjunctiva. 2010 , 45, 1340-6	44
2045	MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. 2010 , 45, 1449-56	39
2044	A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. 2010 , 45, 1427-34	52
2043	Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. 2010 , 45, 1719-27	12
2042	Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. 2010 , 133, 2852-65	143
2041	The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. 2010 , 3, 143-57	41
2040	Long-term physiological side effects after allogeneic bone marrow transplantation. 2010 , 2010, 229-36	35
2039	The chemokine system: a possible therapeutic target in acute graft versus host disease. 2010 , 341, 97-120	18
2038	Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. 2010 , 45, 919-24	22
2037	Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. 2010 , 45, 1442-8	14

2036	Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD. 2010 , 45, 1758-9		4
2035	Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. 2010 , 341, 121-46		12
2034	Suicide gene therapy for graft-versus-host disease. 2010 , 2, 521-37		4
2033	Pathogenesis and management of graft-versus-host disease. 2010 , 30, 75-101		128
2032	Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?. 2010 , 12, 440-54		4
2031	Chronic graft-versus-host disease (GVHD) in children. 2010 , 57, 297-322		87
2030	Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins. 2010 , 3, 633-51		3
2029	Chronic Graft-Versus-Host Disease. 2010 , 189-212		
2028	Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. 2010 , 126, 1000-5		59
2027	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. 2010 , 3, 36		40
2026	Have we made progress in the management of chronic graft-vs-host disease?. 2010 , 23, 529-35		24
2025	Severe chronic graft-versus-host disease of the fasciae and muscles of the hand—case report. 2010 , 73, e69-e71		
2024	Lung function and long-term complications after allogeneic hematopoietic cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 53-61	4-7	28
2023	Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 62-9	4-7	23
2022	Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 123-8	4-7	16
2021	Current challenges in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S146-51	4-7	34
2020	Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation—an increasingly recognized manifestation of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S106-14	4-7	139
2019	Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 403-12	4-7	159

2018	Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 729-38	4-7	6
2017	Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 482-9	4-7	207
2016	Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 809-17	4-7	34
2015	A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 937-47	4-7	86
2014	Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 838-47	4-7	170
2013	Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 948-956	4-7	36
2012	Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 957-66	4-7	28
2011	High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 915-26	4-7	53
2010	Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1362-9	4-7	61
2009	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 871-90	4-7	85
2008	Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1549-56	4-7	34
2007	Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1707-17	4-7	54
2006	Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1611-28	4-7	180
2005	Clinical update on graft-versus-host disease in children. 2010 , 29, 92-105		16
2004	Complicaçõs pulmonares nã infecciosas apõs transplante de cõulas-tronco hematopoiõticas. 2010 , 16, 815-828		1
2003	RNA therapeutics: function, design, and delivery. Preface. 2010 , 629, v-vii		5
2002	Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. 2010 , 45, 1174-80		17
2001	The Chemokine System in Experimental and Clinical Hematology. 2010 ,		5

2000	Management of acute graft-versus-host disease in children. 2010 , 57, 273-95	28
1999	Allogeneic hematopoietic cell transplantation: the state of the art. 2010 , 3, 285-99	116
1998	Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. 2010 , 115, 3437-46	139
1997	Review of chronic graft-versus-host disease in children after allogeneic stem cell transplantation: nursing perspective. 2011 , 28, 6-15	4
1996	The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. 2011 , 11, 687-97	15
1995	Graft-Versus-Host Disease. 2011 , 178.1-178.12	
1994	[Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients]. 2011 , 137, 115-8	4
1993	Loss of Intrahepatic Bile Ducts in Adults. 2011 , 393-403	
1992	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. 2011 , 118, 6438-45	137
1991	Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. 2011 , 118, 3715-20	106
1990	Epigenomics in hematopoietic transplantation: novel treatment strategies. 2011 , 3, 611-23	6
1989	Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. 2011 , 46, 1369-73	51
1988	A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. 2011 , 46, 1455-63	20
1987	Interleukin-2 and regulatory T cells in graft-versus-host disease. 2011 , 365, 2055-66	787
1986	Childhood Leukemia. 2011 ,	6
1985	Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. 2011 , 53, 376-83	12
1984	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 341-50	4-7 80
1983	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1-17	4-7 260

1982	Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 124-32	4-7	24
1981	Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 239-48	4-7	25
1980	Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 167-75	4-7	45
1979	Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 657-63	4-7	39
1978	Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 703-9	4-7	5
1977	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 908-15	4-7	91
1976	Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1051-7	4-7	74
1975	<i>Helicobacter pylori</i> infection and graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 765-9	4-7	7
1974	Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1072-8	4-7	145
1973	Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1187-95	4-7	20
1972	Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1214-21	4-7	9
1971	ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1237-44	4-7	32
1970	Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1316-26	4-7	68
1969	Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1362-74	4-7	125
1968	A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1088-92	4-7	30
1967	Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1343-51	4-7	112
1966	Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1505-11	4-7	30
1965	Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1121-32	4-7	13

1964	A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1619-29	4-7	46
1963	Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1555-61	4-7	16
1962	Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1653-61	4-7	13
1961	Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1698-703	4-7	16
1960	Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1673-8	4-7	24
1959	Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1114-20	4-7	50
1958	Tocilizumab for the treatment of steroid refractory graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1862-8	4-7	92
1957	National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1573-84	4-7	63
1956	Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. 2011 , 46, 1283-95		116
1955	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. 2011 , 117, 4651-7		251
1954	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. 2011 , 117, 6714-20		105
1953	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. 2011 , 118, 5021-30		34
1952	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. 2011 , 117, 3214-9		420
1951	Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. 2011 , 118, 4250-7		71
1950	Influence of glutathione S-transferase T1 donor/recipient mismatch and anti-GSTT1 antibodies in hepatic graft-versus-host-disease. 2011 , 141, 140-4		6
1949	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. 2011 , 42, 254-68		14
1948	Incidence of acute and chronic graft-versus-host disease and donor T-cell chimerism after small bowel or combined organ transplantation. 2011 , 46, 1732-8		30
1947	Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. 2011 , 102, 111-5		54

1946	Extracorporeal photochemotherapy induces arginase 1 in patients with graft versus host disease. 2011 , 24, 100-6	17
1945	Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. 2011 , 25, 163-6	10
1944	HDAC inhibition and graft versus host disease. 2011 , 17, 404-16	67
1943	Critical Illness Involving Children Undergoing Hematopoietic Progenitor Cell Transplantation. 2011 , 1177-1190	1
1942	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. 2011 , 96, 1504-11	46
1941	Treatment of chronic graft-versus-host disease: Past, present and future. 2011 , 46, 153-63	65
1940	Hematopoietic stem cell transplantation. 320-329	
1939	Immune Reactions following Cord Blood Transplantations in Adults. 2011 , 2011, 607569	4
1938	Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen. 2011 , 17, CR480-4	3
1937	Pathophysiology, prevention, and treatment of acute graft-versus-host disease. 2011 , 31	
1936	Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease. 2011 , 52, 779-86	6
1935	Contrast-enhanced ultrasound for differential diagnosis of suspected GvHD in patients after allogeneic transplantation. 2011 , 49, 129-36	9
1934	The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. 2011 , 46, 80-7	32
1933	Tyrosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. 2011 , 11, 1908-31	18
1932	Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies. 2011 , 6, e23827	12
1931	A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. 2011 , 6, e26229	149
1930	Visual acuity and anterior segment findings in chronic graft-versus-host disease. 2011 , 30, 1392-7	25
1929	Histological features of the nasal mucosa in hematopoietic stem cell transplantation. 2011 , 25, e191-5	4

1928	Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation. 2011 , 139, 633-639	13
1927	The spectrum of lung involvement in collagen vascular-like diseases following allogeneic hematopoietic stem cell transplantation: report of 6 cases and review of the literature. 2011 , 90, 146-157	17
1926	A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. 2011 , 118, 4732-9	64
1925	Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. 2011 , 117, 2265-74	77
1924	Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. 2011 , 118, 1140-4	21
1923	Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. 2011 , 117, 3469-72	12
1922	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. 2011 , 117, 6375-82	232
1921	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. 2011 , 118, 456-63	69
1920	Slashing the picture of Dorian Gray. 2011 , 117, 2990	1
1919	Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. 2011 , 118, 1685-92	140
1918	How I conduct a comprehensive chronic graft-versus-host disease assessment. 2011 , 118, 2679-87	33
1917	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. 2011 , 118, 2413-9	146
1916	Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. 2011 , 118, 4472-9	41
1915	Chronic GVHD: a new risk score?. 2011 , 117, 6408-9	4
1914	Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. 2011 , 118, 6446-9	33
1913	Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. 2011 , 118, 4258-64	48
1912	Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantation. 2011 ,	
1911	Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. 2011 , 96, 1072-6	141

1910	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. 2011 , 96, 1528-35	41
1909	Graft-versus-host disease therapy: something else beyond glucocorticoids?. 2011 , 96, 1249-51	6
1908	Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. 2011 , 50, 2149-55	11
1907	Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. 2011 , 96, 150-5	26
1906	Graft-vs-host disease following allogeneic hematopoietic cell transplantation. 2011 , 18, 268-76	42
1905	Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. 2011 , 25, 892-7	20
1904	The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. 2011 , 73, 586-93	29
1903	Leucoderma in chronic graft-versus-host disease: excellent repigmentation with noncultured cellular grafting. 2011 , 165, 435-7	5
1902	German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. 2011 , 165, 18-29	31
1901	Decreased pro-inflammatory cytokines and increased CCR7 expression on T-lymphocyte subsets are predictive of response to extracorporeal photopheresis in patients with GvHD. 2011 , 154, 409-13	5
1900	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. 2011 , 153, 76-82	43
1899	Cutaneous graft-versus-host disease: rationales and treatment options. 2011 , 24, 219-28	16
1898	Acute graft-versus-host disease following hematopoietic stem-cell transplantation. 2011 , 24, 411-23	17
1897	Microchimerism in labial salivary glands of hematopoietic stem cell transplanted patients. 2011 , 17, 484-8	2
1896	A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. 2011 , 86, 305-16	24
1895	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. 2011 , 87, 46-53	24
1894	Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia. 2011 , 87, 172-81	5
1893	Comparison of the occurrence of mold infection among patients receiving chemotherapy for acute leukemia versus patients undergoing stem cell transplantation. 2011 , 87, 419-25	2

1892	Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study. 2011 , 43, 1934-8	12
1891	Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 2011 , 61, 518-27	45
1890	Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient. 2011 , 12, 233-244	6
1889	Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. 2011 , 39, 880-90	6
1888	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. 2011 , 118, 4242-9	169
1887	Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. 2011 , 137, 1293-300	14
1886	Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. 2011 , 15, 127-39	57
1885	[Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD]. 2011 , 62, 139-54; quiz 155	9
1884	[Graft-versus-host disease (GvHD) - an update. Part 2: prognosis and therapy of GvHD]. 2011 , 62, 229-37; quiz 238-9	5
1883	[Histopathology of graft-versus-host disease]. 2011 , 32, 144-51	7
1882	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. 2011 , 93, 206-212	13
1881	Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. 2011 , 93, 375-382	46
1880	Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. 2011 , 93, 532-541	11
1879	Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. 2011 , 94, 266-278	2
1878	High-resolution computed tomography features of pulmonary chronic graft-versus-host disease following hematopoietic stem cell transplantation: histopathological correlation. 2011 , 29, 116-28	1
1877	Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol. 2011 , 9, 24	18
1876	Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. 2011 , 117, 4679-88	76
1875	Graft-versus-Host-Erkrankung der Haut. 2011 , 37, 317-332	

1874	Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. 2011 , 4, 437-52; quiz 453-4	75
1873	Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. 2011 , 258, 660-71	73
1872	Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. 2011 , 46, 232-7	14
1871	Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. 2011 , 46, 192-9	8
1870	Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience. 2011 , 46, 1186-91	27
1869	Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. 2011 , 46, 1418-25	14
1868	Effect of vitamin D treatment in chronic GVHD. 2011 , 46, 1395-7	20
1867	Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study. 2011 , 46, 1551-6	48
1866	Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies. 2011 , 46, 1540-4	6
1865	Successful control of steroid-intolerant Evans' syndrome associated with allogeneic peripheral blood hematopoietic stem cell transplant by rituximab. 2011 , 52, 528-30	3
1864	Biomarkers in chronic graft-versus-host disease. 2011 , 4, 329-42	17
1863	Treatment of chronic graft-versus-host disease in 2011. 2011 , 18, 414-20	61
1862	Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. 2011 , 38, 470-2	11
1861	Small airways function declines after allogeneic haematopoietic stem cell transplantation. 2011 , 38, 1180-8	27
1860	Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. 2011 , 17, 6878-87	12
1859	Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. 2011 , 1, e16	114
1858	The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. 2011 , 96, 1678-84	56
1857	Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. 2011 , 46, 1363-8	17

1856	Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. 2011 , 5, 127-35	12
1855	Nail fold capillaroscopy differs widely between systemic sclerosis and chronic graft vs host disease of the skin. 2011 , 50, 1168-9	9
1854	Polyserositis as a manifestation of graft-versus-host disease. 2011 , 28, 691-3	2
1853	Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. 2011 , 46, 516-22	22
1852	GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. 2011 , 46, 668-75	18
1851	Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. 2011 , 46, 641-9	20
1850	Transmural penetration of intravenously applied microbubbles during contrast-enhanced ultrasound as a new diagnostic feature in patients with GVHD of the bowel. 2011 , 46, 1006-11	16
1849	[Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011]. 2011 , 98, 889-99	1
1848	Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. 2011 , 26, 251-60	20
1847	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. 2011 , 46, 690-701	17
1846	High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. 2011 , 46, 1104-12	33
1845	Oral chronic graft-vs.-host disease characterization using the NIH scale. 2012 , 91, 45S-51S	17
1844	Iron overload in allogeneic hematopoietic stem cell transplant recipients. 2012 , 136, 532-8	12
1843	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. 2012 , 47, 337-41	168
1842	Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging. 2012 , 47, 1067-74	17
1841	Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. 2012 , 47, 494-8	49
1840	Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT. 2012 , 47, 739-41	3
1839	Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. 2012 , 47, 1020-9	34

1838	Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. 2012, 47, 824-30	49
1837	Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. 2012, 47, 107-14	29
1836	Tear physiology in dry eye associated with chronic GVHD. 2012, 47, 115-9	27
1835	Surgical resection as definitive treatment for refractory GVHD of the colon. 2012, 47, 1366-7	5
1834	Hepatic GVHD leading to cirrhosis after allogeneic hematopoietic SCT. 2012, 47, 1484-5	7
1833	Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. 2012, 47, 1470-3	65
1832	Ocular graft-versus-host disease. 2012, 12, 540-7	76
1831	Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. 2012, 47, 33-9	53
1830	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de M�dula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. 2012, 97, 310-7	158
1829	Future trends in hematopoietic stem cell transplantation. 2012, 43, 165-70	4
1828	Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. 2012, 367, 135-45	203
1827	Peripheral-blood stem cells versus bone marrow from unrelated donors. 2012, 367, 1487-96	620
1826	Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. 2012, 47, 581-8	34
1825	Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. 2012, 47, 663-8	27
1824	M-CSF attenuates severity of chronic GVHD after unrelated BMT. 2012, 47, 426-9	6
1823	[Chronic graft versus host disease (GvHD): causes, manifestation, diagnosis and treatment option]. 2012, 137, 2166-70	
1822	Autologous platelet lysate for treatment of refractory ocular GVHD. 2012, 47, 1558-63	40
1821	Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. 2012, 12, 1017-30	8

1820	Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. 2012 , 47, 981-4	23
1819	Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. 2012 , 26, 633-43	41
1818	Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. 2012 , 26, 746-56	74
1817	NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. 2012 , 26, 536-42	30
1816	Mucosal microvilli in dry eye patients with chronic GVHD. 2012 , 47, 416-25	23
1815	Long-term oral complications of allogeneic haematopoietic SCT. 2012 , 47, 265-70	36
1814	Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. 2012 , 54, 1053-63	164
1813	Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. 2012 , 189, 222-33	67
1812	Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. 2012 , 56, 5247-52	31
1811	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. 2012 , 5, 1-30	61
1810	Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. 2012 , 97, 717-22	18
1809	Clinical Results of Extracorporeal Photopheresis. 2012 , 39, 254-262	11
1808	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2012 ,	1
1807	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. 2012 , 97, 1882-9	72
1806	Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. 2012 , 142, 159-167	79
1805	Section 5: Extracorporeal Photopheresis in Chronic Graft-versus-Host Disease. 2012 , 97-134	
1804	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. 2012 , 97, 1187-95	10
1803	Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation. 2012 ,	

1802	Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. 2012 , 93, 1265-9	37
1801	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2012 ,	2
1800	Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation. 2012 , 93, 949-57	15
1799	Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. 2012 , 31, 299-310	93
1798	Lethal pulmonary complications after pediatric allogeneic hematopoietic stem cell transplantation. 2012 , 31, 115-9	5
1797	Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. 2012 , 97, 710-6	34
1796	Hematopoietic stem cell and natural killer cell transplantation. 527-548	
1795	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. 2012 , 97, 451-8	62
1794	Neutropenic Enterocolitis and Graft Versus Host Disease. 2012 , 83-92	
1793	Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. 2012 , 119, 6373-8	86
1792	How we treat oral chronic graft-versus-host disease. 2012 , 120, 3407-18	61
1791	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. 2012 , 119, 2657-64	116
1790	Exciting new murine model of cGVHD. 2012 , 119, 1331-2	1
1789	Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. 2012 , 120, 4246-55	53
1788	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. 2012 , 120, 2545-52; quiz 2774	91
1787	Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. 2012 , 120, 4256-62	101
1786	cGVHD of skin: simple tools, great advances. 2012 , 120, 2537-8	
1785	Keep up the heat on IL-1. 2012 , 120, 2538-9	10

1784	Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. 2012 , 120, 5089-90		32
1783	Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. 2012 , 49, 83-93		50
1782	Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. 2012 , 49, 15-24		35
1781	Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. 2012 , 49, 73-82		28
1780	Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. 2012 , 120, 4443-4		18
1779	Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease. 2012 , 188, 5142-9		31
1778	Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. 2012 , 259, 2699-706		46
1777	Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. 2012 , 44, 168-80		74
1776	Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation. 2012 , 40, 677-84		39
1775	Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1479-87	4-7	23
1774	Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1552-63	4-7	33
1773	Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1649-55	4-7	21
1772	Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1368-77	4-7	43
1771	Extensive dental caries in patients with oral chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1573-9	4-7	24
1770	The use of monoclonal antibodies in immune-mediated hematologic disorders. 2012 , 96, 583-619, xi		4
1769	HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1700-8	4-7	95
1768	Comparison of pulmonary complications after nonmyeloablative and conventional allogeneic hematopoietic cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1827-34	4-7	15
1767	TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1525-32	4-7	44

1766	Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1876-82	4-7	25
1765	Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1211-8	4-7	137
1764	Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1600-7	4-7	21
1763	Validation of measurement scales in ocular graft-versus-host disease. 2012 , 119, 487-93		68
1762	Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: a study by the Hellenic association of hematology. 2012 , 46, 173-80		11
1761	The role of the extracorporeal photopheresis in the management of the graft-versus-host disease. 2012 , 46, 211-9		10
1760	Extracorporeal photopheresis in refractory chronic graft-versus-host disease: the influence on peripheral blood T cell subpopulations. A study by the Hellenic Association of Hematology. 2012 , 46, 181-8		22
1759	Emergence of T cells that recognize nonpolymorphic antigens during graft-versus-host disease. 2012 , 119, 6354-64		19
1758	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. 2012 , 119, 1570-80		178
1757	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. 2012 , 119, 6145-54		87
1756	Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. 2012 , 66, 515.e1-18; quiz 533-4		35
1755	Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 84-91	4-7	44
1754	Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 134-40	4-7	20
1753	Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 273-9	4-7	12
1752	Stable long-term pulmonary function after myeloablative double cord blood transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 309-13	4-7	2
1751	Mesenchymal stromal cells: a new tool against graft-versus-host disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 822-40	4-7	81
1750	Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 466-72	4-7	36
1749	Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 805-12	4-7	72

1748	Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S46-52	4-7	17
1747	Understanding chronic GVHD from different angles. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S184-8	4-7	11
1746	Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 913-21	4-7	31
1745	Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 318-23	4-7	17
1744	Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 951-7	4-7	22
1743	Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1044-54	4-7	36
1742	Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1069-75	4-7	13
1741	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 348-71	4-7	261
1740	Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1099-107	4-7	44
1739	Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1136-43	4-7	21
1738	Neuropathy in chronic graft-versus-host disease caused by donor T cells. 2012 , 46, 610-1		7
1737	Potential biomarkers for early detection of acute graft-versus-host disease. 2012 , 6, 351-63		3
1736	Treatment of relapsed myelodysplastic syndrome following double umbilical cord blood transplantation with interferon alpha and 5-azacytidine. 2012 , 159, 602-4		1
1735	History of hematopoietic stem cell transplantation: evolution and perspectives. 2012 , 43, 81-90		18
1734	Cutaneous graft-versus-host disease--clinical considerations and management. 2012 , 43, 101-15		14
1733	UV treatment of chronic skin graft-versus-host disease--focus on UVA1 and extracorporeal photopheresis. 2012 , 43, 116-31		4
1732	Acute graft-versus-host disease in pediatric allogeneic hematopoietic stem cell transplantation. Single-center experience during 10 yr. 2012 , 16, 887-93		17
1731	Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. 2012 , CD009159		23

1730	Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. 2012 , 20, 2347-54		45
1729	Prevention of graft-vs.-host disease. 2012 , 13, 1737-50		13
1728	Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. 2012 , 49, 43-58		26
1727	Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management. 2012 , 12, 265-82		62
1726	Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain. 2012 , 34, 1774-87		8
1725	Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. 2012 , 36, 1147-51		39
1724	Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1734-44	4-7	21
1723	Clinical benefit of response in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1517-24	4-7	38
1722	Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors. 2012 , 14, 194-204		9
1721	Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1905-10	4-7	11
1720	Factors influencing outcome and incidence of late complications in children who underwent allogeneic hematopoietic stem cell transplantation for hemoglobinopathy. 2012 , 29, 694-703		15
1719	Advances in Stem Cell Research. 2012 ,		1
1718	Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1859-66	4-7	201
1717	Spender T-Zellen kontrolliert lenken. 2012 , 15, 22-26		
1716	Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients. 2012 , 91, 1953-8		17
1715	Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. 2012 , 47, 374-9		40
1714	Leukemia and Related Disorders. 2012 ,		3
1713	Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. 2012 , 47, 1552-7		4

1712	Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1250-4	4-7	28
1711	Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. 2012 , 47, 1428-35		65
1710	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. 2012 , 47, 1274-82		36
1709	Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. 2012 , 32, 1390-9		31
1708	Bronchiolitis. 2012 , 32, 601-19		9
1707	CD4 ⁺ CD25 ^{high} CD127 ^{low} regulatory T cells in peripheral blood are not an independent factor for chronic graft-versus-host disease after allogeneic stem cell transplantation. 2012 , 2012, 606839		7
1706	Biomarkers for the detection of graft-versus-host disease in cancer patients after bone marrow transplantation. 2012 , 29		1
1705	Are we making progress in GVHD prophylaxis and treatment?. 2012 , 2012, 251-264		35
1704	Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. 2012 , 53, 1054-7		9
1703	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. 2012 , 119, 296-307		416
1702	Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children. 2012 , 58, 780-4		24
1701	The expanding frontier of hematopoietic cell transplantation. 2012 , 82, 271-9		13
1700	Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD. 2012 , 53, 200-12		19
1699	Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation. 2012 , 96, 146-8		
1698	Non-atopic IgE and eosinophil cationic protein after allogeneic hematopoietic stem cell transplantation in children. 2012 , 91, 949-56		0
1697	Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation. 2012 , 171, 1095-101		4
1696	Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease. 2012 , 16, 565-70		4
1695	The lack of memory B cells including T cell independent IgM ⁺ IgD ⁺ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. 2012 , 25, 87-96		17

1694	Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. 2012 , 156, 656-66	94
1693	Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. 2012 , 52, 1086-91	15
1692	Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. 2012 , 52, 1348-53	8
1691	Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. 2012 , 52, 2007-15	37
1690	Immunity after (re)vaccination of paediatric patients following haematopoietic stem cell transplantation. 2012 , 101, e373-7	10
1689	Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. 2012 , 88, 52-60	42
1688	Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. 2012 , 88, 46-51	15
1687	Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. 2012 , 88, 504-9	11
1686	Development of psoriasis 10 years after allogeneic hematopoietic cell transplantation from non-psoriatic donor: Further evidences for genetics and immunopathogenesis of psoriasis. 2012 , 39, 1072-4	2
1685	Diagnosis and management of chronic graft-versus-host disease. 2012 , 158, 46-61	121
1684	Diagnosis and management of acute graft-versus-host disease. 2012 , 158, 30-45	232
1683	Organ-specific management and supportive care in chronic graft-versus-host disease. 2012 , 158, 62-78	49
1682	Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. 2012 , 26, 635-43	41
1681	Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. 2012 , 26, E168-75	17
1680	Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit. 2012 , 12, 44	4
1679	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. 2012 , 87, 9-14	15
1678	Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. 2012 , 95, 182-8	78
1677	Les complications pulmonaires non infectieuses de l'allogreffe de cellules souches hématopoïétiques. 2012 , 21, 418-425	

1676	Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients. 2013 , 19, 18-36		23
1675	Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants. 2013 , 40, 108-15		4
1674	Isomorphic sclerotic-type cutaneous chronic graft-versus-host disease: report and review of chronic graft-versus-host disease in a cutaneous immunocompromised district. 2013 , 3, 215-22		3
1673	Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?. 2013 , 48, 1224-9		31
1672	Mesenchymal stem cells as cellular immunotherapeutics in allogeneic hematopoietic stem cell transplantation. 2013 , 130, 131-62		3
1671	TLI in refractory chronic GVHD. 2013 , 48, 854-8		6
1670	The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. 2013 , 146, 104-11		12
1669	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). 2013 , 139, 1397-404		11
1668	New developments in acute graft-versus-host disease. 2013 , 6, 98-101		
1667	Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center. 2013 , 48, 129-34		17
1666	Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. 2013 , 92, 1121-8		24
1665	Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. 2013 , 92, 497-504		28
1664	Graft-versus-host disease: state of the science. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S102-8	4-7	16
1663	Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 973-80	4-7	31
1662	Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1167-74	4-7	13
1661	Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 949-57	4-7	61
1660	Genital chronic GVHD in men after hematopoietic stem cell transplantation: a single-center cross-sectional analysis of 155 patients. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1574-80	4-7	29
1659	Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1374-80	4-7	64

1658	Citation analysis of the dry eye literature. 2013 , 11, 35-46		6
1657	Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1731-9	4-7	40
1656	Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. 2013 , 148, 124-35		9
1655	Lung function after allogeneic hematopoietic stem cell transplantation in children: a longitudinal study in a population-based cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1348-54	4-7	15
1654	Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. 2013 , 122, 1678-84		54
1653	Ocular graft-versus-host disease: a review. 2013 , 58, 233-51		134
1652	Treatment options for graft-versus-host disease. 2013 , 1, 731-743		1
1651	Buka's Emergencies in Dermatology. 2013 ,		
1650	Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. 2013 , 31, 4416-23		27
1649	Nailfold capillary abnormalities in sclerodermatous chronic GVHD. 2013 , 48, 1574-7		8
1648	Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. 2013 , 48, 1421-8		14
1647	Comorbidity burden in patients with chronic GVHD. 2013 , 48, 1429-36		15
1646	Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1204-9	4-7	14
1645	Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. 2013 , 41, 772-8		11
1644	Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. 2013 , 4, 320-34		44
1643	Emerging technologies for oral diagnostics: lessons from chronic graft-versus-host disease. 2013 ,		
1642	Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. 2013 , 92, 1379-88		28
1641	NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. 2013 , 24, 1363-70		27

1640 Mesenchymal Stem Cells - Basics and Clinical Application II. **2013,**

1639	Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. 2013, 48, 819-24		52
1638	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. 2013, 27, E21-9		15
1637	Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1059-64	4-7	46
1636	Graft-versus-host disease biomarkers: omics and personalized medicine. 2013, 98, 275-92		31
1635	The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. 2013, 57, 125-39		7
1634	Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation. 2013, 48, 1046-9		16
1633	Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure. 2013, 48, 678-83		14
1632	Increased complications and morbidity in children with hemophagocytic lymphohistiocytosis undergoing hematopoietic stem cell transplantation. 2013, 27, 248-54		10
1631	A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepea and rabbit antithymocyte globulin. 2013, 54, 1713-8		1
1630	Discovery and validation of graft-versus-host disease biomarkers. 2013, 121, 585-94		109
1629	Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. 2013, 48, 439-45		35
1628	"Assessment of chronic sclerodermoid Graft-versus-Host Disease patients, using 20 MHz high-frequency ultrasonography and cutometer methods". 2013, 19, e417-22		16
1627	Assessing response of therapy for acute and chronic graft-versus-host disease. 2013, 6, 103-7		6
1626	Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. 2013, 33, 22-30		26
1625	Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 904-11	4-7	54
1624	Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 754-9	4-7	63
1623	Ocular manifestations of graft-versus-host disease. 2013, 27, 215-22		52

1622	Providing personalized prognostic information for adult leukemia survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1600-7	4-7	12
1621	National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 632-9	4-7	73
1620	Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 589-96	4-7	59
1619	Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation. 2013 , 37, 1046-51		5
1618	Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1094-101	4-7	21
1617	Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 792-8	4-7	22
1616	Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 562-8	4-7	56
1615	Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 143-9	4-7	26
1614	Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 82-6	4-7	5
1613	Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 804-11	4-7	10
1612	Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 602-6	4-7	71
1611	Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 888-92	4-7	13
1610	Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 2013 , 45, 3375-80		21
1609	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 576-83	4-7	1
1608	Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 240-6	4-7	7
1607	T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. 2013 , 31, 1310-6		387
1606	Graft-versus-host-disease after double cord blood transplantation: a new look at its characteristics. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 847-8	4-7	3
1605	Heart failure after allogeneic hematopoietic stem cell transplantation. 2013 , 167, 2502-6		8

1604	Diagnostyka i leczenie pŕych nieinfekcyjnych powikŕdŕonych u chorych po transplantacji allogenicznym komŕek krwiotwŕczych. 2013 , 44, 392-398		
1603	A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 799-803	4-7	58
1602	Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1719-24	4-7	32
1601	High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 75-81	4-7	59
1600	Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 860-6	4-7	12
1599	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1087-93	4-7	11
1598	Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 784-91	4-7	37
1597	Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 102-8	4-7	45
1596	Principles of haematopoietic stem cell transplantation. 2013 , 41, 302-305		1
1595	Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 967-72	4-7	31
1594	More than skin deep? Emerging therapies for chronic cutaneous GVHD. 2013 , 48, 323-37		17
1593	Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. 2013 , 27, 1229-35		163
1592	Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. 2013 , 19, 372-7		147
1591	Graft versus host disease: clinical evaluation, diagnosis and management. 2013 , 251, 1257-66		51
1590	Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 767-76	4-7	44
1589	Characteristics of chronic GVHD after cord blood transplantation. 2013 , 48, 1285-90		26
1588	Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. 2013 , 48, 491-501		29
1587	Risk and prognostic factors for acute GVHD based on NIH consensus criteria. 2013 , 48, 587-92		48

1586	Nutritional support in patients with GVHD of the digestive tract: state of the art. 2013 , 48, 474-82	42
1585	Special Care of Blood and Marrow Stem Transplant Patients. 2013 , 1321-1345	
1584	Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. 2013 , 27, 1659-65	110
1583	Th1/Th2 and Tc1/Tc2 cells. 2013 , 223-244	
1582	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. 2013 , 299-326	
1581	Role of Th17 cells and interleukin 17 in graft-versus-host disease and graft-versus-leukemia reactivity. 2013 , 271-297	
1580	Proteomics in graft-versus-host disease and graft-versus-leukemia. 2013 , 449-478	2
1579	Cancer immunotherapies, their safety and toxicity. 2013 , 12, 631-45	94
1578	Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. 2013 , 48, 1296-301	23
1577	Allo-SCT using BU, CY and melphalan for children with AML in second CR. 2013 , 48, 651-6	19
1576	GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM. 2013 , 48, 715-21	22
1575	IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. 2013 , 48, 722-8	20
1574	Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?. 2013 , 48, 203-9	27
1573	Ocular Graft-versus-Host Disease. 2013 , 179-182	
1572	Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease. 2013 , 97, 263-71	9
1571	Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 981-7	4-7 36
1570	Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 607-15	4-7 22
1569	Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1310-22	4-7 37

1568	Treatment and management of graft-versus-host disease: improving response and survival. 2013 , 4, 366-78	93
1567	Sensitive GC-MS/MS method to measure deuterium labeled deoxyadenosine in DNA from limited mouse cell populations. 2013 , 85, 4613-20	9
1566	Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 2013 , 15, 259-67	42
1565	A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. 2013 , 48, 278-83	20
1564	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. 2013 , 48, 1098-103	15
1563	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. 2013 , 48, 249-52	14
1562	Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. 2013 , 48, 708-14	31
1561	Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient. 2013 , 48, 144-5	1
1560	Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. 2013 , 48, 1179-84	12
1559	Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR. 2013 , 48, 1450-5	19
1558	Ocular graft-versus-host disease after allogeneic transplantation. 2013 , 17, 621-6	7
1557	Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose. 2013 , 48, 508-13	29
1556	Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT. 2013 , 48, 814-8	8
1555	Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. 2013 , 48, 1123-8	36
1554	Active thrombopoiesis is associated with worse severity and activity of chronic GVHD. 2013 , 48, 1569-73	6
1553	Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation. 2013 , 48, 1578-80	6
1552	Multidetector row computed tomography quantification of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a pilot study. 2013 , 28, 114-20	7
1551	Management of noninfectious lung injury following hematopoietic cell transplantation. 2013 , 25, 187-94	15

1550	H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. 2013 , 110, 3005-10	25
1549	Skin Signs of Graft Versus Host Disease. 2013 , 1,	
1548	Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease. 2013 , 130, 34-43	6
1547	High-dose cyclophosphamide therapy associated with diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation. 2013 , 86, 453-61	5
1546	Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. 2013 , 70, 1383-91	19
1545	Small airways diseases, excluding asthma and COPD: an overview. 2013 , 22, 131-47	55
1544	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. 2013 , 2013, 414959	8
1543	Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan. 2013 , 2013, 232519	3
1542	Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. 2013 , 33, 893-901	8
1541	The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. 2013 , 88, 497-502	27
1540	Cutaneous graft versus host disease in pediatric multivisceral transplantation. 2013 , 30, 335-41	12
1539	Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation. 2013 , 91, 442-7	12
1538	A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. 2013 , 26, 631-9	18
1537	Graft-versus-host disease of the skin and adjacent mucous membranes. 2013 , 11, 477-95	10
1536	Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. 2013 , 88, 874-82	5
1535	High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. 2013 , 27, E56-63	25
1534	The use of novel Therakos[Celler] for extracorporeal photopheresis in treatment of graft-versus-host disease in paediatric patients. 2013 , 163, 357-64	18
1533	A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. 2013 , 27, E1-2	5

1532	High frequency of CD29 ^{high} intermediate monocytes correlates with the activity of chronic graft-versus-host disease. 2013 , 91, 280-2	7
1531	Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. 2013 , 19, 327-46	60
1530	Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. 2013 , 43, 838-50	16
1529	Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children. 2013 , 54, 105-9	2
1528	Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. 2013 , 48, 703-7	25
1527	Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4 ⁺ and CD8 ⁺ T cells. 2013 , 191, 488-99	100
1526	Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. 2013 , 27, 1196-201	13
1525	The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series. 2013 , 54, 1020-7	3
1524	Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. 2013 , 15, 233-42	94
1523	Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. 2013 , 31, 1530-8	164
1522	International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). 2013 , 3, 3419	120
1521	Graft-versus-Host-Erkrankung der Haut und angrenzenden Schleimh�ute. 2013 , 11, 477-497	7
1520	Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. 2013 , 122, 2751-6	34
1519	CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. 2013 , 121, 1886-95	61
1518	Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. 2013 , 121, 219-25	53
1517	Phase 2 clinical trial of rapamycin-resistant donor CD4 ⁺ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. 2013 , 121, 2864-74	27
1516	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. 2013 , 121, 5098-103	74
1515	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. 2013 , 121, 2340-6	43

1514	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. 2013 , 121, 5113-23	399
1513	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. 2013 , 122, 1510-7	93
1512	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. 2013 , 122, 4111-8	69
1511	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. 2013 , 122, 1813-21	264
1510	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. 2013 , 122, 4129-39	445
1509	Overview of acute and chronic graft-versus-host disease. 48-49	
1508	Chronic graft-versus-host disease. 79-100	
1507	Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease. 2013 , 98, 41-9	11
1506	Effects of exercise interventions in graft-versus-host disease models. 2013 , 22, 2409-20	11
1505	Prevalence of dry eye syndrome after allogeneic hematopoietic stem cell transplantation. 2013 , 32, e97-101	26
1504	Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. 2013 , 96, 34-41	18
1503	Evaluation of intima-media thickness of carotid artery in patients with chronic graft-versus-host disease using ultrasound. 2013 , 5, 19-23	
1502	Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. 2013 , 95, 623-8	29
1501	Outcome predictors of allogeneic hematopoietic stem cell transplant. 2013 , 345, 33-8	10
1500	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. 2013 , 98, 776-83	31
1499	[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 7. Hematopoietic stem cell transplantation for leukemia: complications]. 2013 , 102, 1737-43	
1498	Diagnosis and treatment of graft-versus-host disease. 311-329	1
1497	Organ-related and miscellaneous complications. 348-410	1

1496	Bilateral corneal ulceration in ocular graft-versus-host disease. 2013 , 7, 2153-8	20
1495	Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 2013 , 48, 16-23	7
1494	Chronic graft-versus-host disease: clinical presentation of multiple lesions of lichenoid and atrophic pattern. 2013 , 88, 799-802	2
1493	The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients \geq 50 years from the Czech acute leukaemia clinical register (alert). 2013 , 60, 576-83	2
1492	MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease?. 2013 , 4, 420	12
1491	The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 2013 ,	
1490	Secondary Lymphoma of the Parotid Gland: Clinical Experience. 2013 , 92, 63-63	1
1489	Esophageal Graft-Versus-Host Disease. 2013 , 92, 64-64	1
1488	Oral chronic graft-versus-host disease: analysis of dendritic cells subpopulations. 2014 , 89, 632-7	5
1487	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. 2014 , 49, 100-6	38
1486	Pathophysiology of the Skin and Oral Squamous Mucosa in Allogeneic Hematopoietic Stem Cell Transplantation. 2014 , 722-740	
1485	Ocular surface evaluation in allogeneic hematopoietic stem cell transplantation patients. 2014 , 24, 655-66	17
1484	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. 2014 , 124, 4867-76	132
1483	Clinical Manifestations and Risk Factors of Ocular Graft-versus-Host Disease (GVHD) after Hematopoietic Stem Cell Transplantation. 2014 , 55, 969	1
1482	Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: Case series. 2014 , 19, e212-9	6
1481	Adult human mesenchymal stromal cells and the treatment of graft versus host disease. 2014 , 7, 45-52	17
1480	Reduction of intramedullary apoptosis after stem cell transplantation in black african variant of pediatric sickle cell anemia. 2014 , 6, e2014054	2
1479	Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia. 2014 , 2014,	0

1478	Isolated intestinal manifestation of graft-versus-host disease following renal transplantation. 2014 , 2,	
1477	Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency. 2014 , 1007-1041	
1476	Clinical Ophthalmic Oncology. 2014 ,	2
1475	Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD. 2014 , 49, 800-5	11
1474	Juvenile arthritis after haematopoietic stem cell transplantation. 2014 , 49, 1244-5	1
1473	Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. 2014 , 49, 1382-8	6
1472	Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials. 2014 , 49, 236-40	5
1471	Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. 2014 , 49, 1084-8	26
1470	Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. 2014 , 49, 616-21	22
1469	Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. 2014 , 49, 704-8	18
1468	Acute disseminated encephalomyelitis following allo-SCT: central nervous system manifestation of GVHD. 2014 , 49, 854-6	9
1467	Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. 2014 , 49, 622-7	9
1466	Differences in health behaviour between recipients of allogeneic haematopoietic SCT and the general population: a matched control study. 2014 , 49, 1223-30	11
1465	Aerobic exercise capacity at long-term follow-up after paediatric allogeneic haematopoietic SCT. 2014 , 49, 1393-9	7
1464	Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. 2014 , 49, 1162-9	27
1463	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. 2014 , 55, 1106-12	21
1462	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. 2014 , 99, 1618-23	23
1461	Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. 2014 , 49, 206-11	27

1460	Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. 2014 , 49, 1016-21	20
1459	Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children. 2014 , 49, 1521-7	15
1458	Application of CIBMTR risk score to NIH chronic GVHD at individual centers. 2014 , 123, 453-5	13
1457	Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. 2014 , 49, 824-30	73
1456	NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. 2014 , 49, 561-6	5
1455	Risk factors and organ involvement of chronic GVHD in Japan. 2014 , 49, 228-35	38
1454	Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease. 2014 , 28, 2016-27	27
1453	Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. 2014 , 49, 426-33	75
1452	Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. 2014 , 49, 812-7	20
1451	Histopathologic diagnosis of chronic graft-versus-host disease of the oral mucosa according to the National Institutes of Health Consensus. 2014 , 12, 204-10	3
1450	Bilateral Inflammatory Optic Neuropathy Related to Graft versus Host Disease Following Allogeneic Bone Marrow Transplantation for Hodgkin Disease. 2014 , 38, 224-229	4
1449	Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. 2014 , 49, 11-6	10
1448	IL-17 genetic and immunophenotypic evaluation in chronic graft-versus-host disease. 2014 , 2014, 571231	4
1447	Oral complications in hematopoietic stem cell recipients: the role of inflammation. 2014 , 2014, 378281	35
1446	Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome. 2014 , 2, 81-86	1
1445	Review of therapies for the treatment of oral chronic graft-versus-host disease. 2014 , 18, 76-81	2
1444	The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. 2014 , 49, 55-61	32
1443	Autologous GVHD?. 2014 , 49, 1349-51	12

1442	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. 2014 , 49, 1412-8	18
1441	Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells. 2014 , 3, 1023-31	19
1440	Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 , 43, 221-32	5
1439	New insight for the diagnosis of gastrointestinal acute graft-versus-host disease. 2014 , 2014, 701013	21
1438	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. 2014 , 124, 1363-71	52
1437	Effects of aGVHD and cGVHD according to relapse status on survival rate in patients with acute lymphocytic leukemia. 2014 , 19, 441-7	3
1436	Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia. 2014 , 99, e199-200	27
1435	Graft-versus-host disease in oncology nursing practice. 2014 , 23, S4, S6, S8-10	
1434	Biomarkers for fatal immune response to stem cell treatment could reduce mortality. 2014 , 8, 65-8	3
1433	Caring for the long-term survivor after allogeneic stem cell transplantation. 2014 , 2014, 495-503	11
1432	Non-infectious respiratory disease in non-HIV immunocompromised patients. 2014 , 75, 691-7	2
1431	Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. 2014 , 61, 2324-5	14
1430	Malnutrition in patients with chronic GVHD. 2014 , 49, 1300-6	28
1429	NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. 2014 , 49, 1513-20	23
1428	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. 2014 , 49, 1492-7	3
1427	Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. 2014 , 171, 63-8	5
1426	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. 2014 , 49, 895-901	34
1425	Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models. 2014 , 49, 649-56	13

1424	Referral to transplant center for hematopoietic cell transplantation. 2014 , 28, 1201-13	6
1423	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. 2014 , 99, 1762-8	24
1422	Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. 2014 , 89, 404-9	27
1421	Assessment of joint and fascia manifestations in chronic graft-versus-host disease. 2014 , 66, 1044-52	42
1420	Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al. 2014 , 66, 2646-8	6
1419	Glomerular diseases associated with chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: case reports. 2014 , 46, 3616-9	5
1418	Eosinophils in the blood of hematopoietic stem cell transplanted patients are activated and have different molecular marker profiles in acute and chronic graft-versus-host disease. 2014 , 2, 99-113	7
1417	Malar rash in a stem cell transplant recipient. 2014 , 312, 547-8	
1416	Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. 2014 , 79, 1363-70	19
1415	Graft-versus-host disease: why have we not made more progress?. 2014 , 21, 141-7	32
1414	Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease. 2014 , 98, 470-4	12
1413	Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. 2014 , 98, 348-53	14
1412	Tear osmolarity in ocular graft-versus-host disease. 2014 , 33, 1252-6	25
1411	Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung. 2014 , 21, 301-20	41
1410	A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. 2014 , 20, 172-82	35
1409	Cholestasis in the Hospitalized Patient. 2014 , 201-228	
1408	Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant. 2014 , 14, 14	1
1407	Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. 2014 , 49, 49-54	31

1406	Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 742-7	4.7	5
1405	Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1163-8	4.7	19
1404	Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 776-80	4.7	17
1403	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 724-9	4.7	120
1402	Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 111-7	4.7	21
1401	A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 354-60	4.7	28
1400	Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 337-44	4.7	60
1399	Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1176-82	4.7	14
1398	Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 387-95	4.7	30
1397	Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1341-8	4.7	43
1396	The difficulty in diagnosing cord colitis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 906-7	4.7	3
1395	High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1156-62	4.7	18
1394	Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?. 2014 , 14, 235-48		7
1393	A safety and feasibility study with platelet lysate expanded bone marrow mesenchymal stromal cells for the treatment of acute graft-versus-host disease in Brazil. 2014 , 55, 1203-5		12
1392	Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. 2014 , 49, 168-73		181
1391	Pancreatic atrophy in patients with chronic graft-versus-host disease. 2014 , 39, 342-7		6
1390	Arresting rampant dental caries with silver diamine fluoride in a young teenager suffering from chronic oral graft versus host disease post-bone marrow transplantation: a case report. 2014 , 7, 3		18
1389	Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study. 2014 , 22, 295-305		8

1388	Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. 2014 , 49, 532-8		16
1387	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. 2014 , 164, 396-408		64
1386	Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 495-500	4.7	35
1385	Thinking out of the box--new approaches to controlling GVHD. 2014 , 9, 73-84		5
1384	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 549-55	4.7	38
1383	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. 2014 , 38, 551-6		8
1382	Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 890-5	4.7	105
1381	Oral graft-versus-host disease. 2014 , 58, 351-68		26
1380	Tc1 clonal T cell expansion during chronic graft-versus-host disease-associated hypereosinophilia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 739-42	4.7	1
1379	Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve. 2014 , 18, 524-6		10
1378	Concise review: the bone marrow niche as a target of graft versus host disease. 2014 , 32, 1420-8		18
1377	Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 135-8	4.7	39
1376	Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 375-81	4.7	159
1375	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 46-52	4.7	72
1374	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. 2014 , 15, 87-95		100
1373	Immune cell subset counts associated with graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 450-62	4.7	38
1372	Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. 2014 , 49, 116-21		20
1371	Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. 2014 , 49, 545-52		38

1370	Distress, problems and supportive care needs of patients treated with auto- or allo-SCT. 2014 , 49, 292-8		24
1369	Increased Th17/Treg ratio in chronic liver GVHD. 2014 , 49, 539-44		38
1368	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2014 , CD009898		1
1367	Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. 2014 , CD010189		50
1366	Relative incidences and outcomes of Clostridium difficile infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. 2014 , 16, 412-20		14
1365	Entrapment syndrome of multiple nerves in graft-versus-host disease. 2014 , 49, 138-42		4
1364	Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia. 2014 , 14, e225-8		7
1363	Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1996-2003	4-7	42
1362	Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2034-41	4-7	26
1361	A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. 2014 , 18, 602-8		9
1360	A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. 2014 , 18, 609-16		9
1359	Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. 2014 , 49, 1481-5		45
1358	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. 2014 , CD010280		22
1357	Current issues in chronic graft-versus-host disease. 2014 , 124, 374-84		263
1356	Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. 2014 , 14, 493-500		5
1355	Immunologic resolution of human chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1508-15	4-7	10
1354	[Managing late-effects after allogeneic stem cell transplantation in children: recommendations from the SFGM-TC]. 2014 , 62, 212-7		1
1353	Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1722-8	4-7	9

1352	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. 2014 , 49, 1475-80		38
1351	Characterization of oral involvement in acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1717-21	4-7	25
1350	The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. 2014 , 49, 1498-504		10
1349	Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1758-66	4-7	39
1348	Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. 2014 , 108, 1525-33		28
1347	Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. 2014 , 93, 273-80		17
1346	Cholestatic Liver Disease. 2014 ,		6
1345	Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation. 2014 , 27, 1253-62		9
1344	Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study. 2014 , 49, 1093-7		23
1343	Trasplante en hematología: seguimiento de un paciente tratado con un aloinjerto. 2014 , 18, 1-11		
1342	Immunology of hematopoietic stem cell transplant. 2014 , 43, 858-87		14
1341	Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. 2014 , 32, 3497-505		175
1340	Eosinophils from hematopoietic stem cell recipients suppress allogeneic T cell proliferation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1891-8	4-7	11
1339	Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1828-34	4-7	40
1338	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4-7	37
1337	[Complications after allogeneic bone marrow and stem cell transplantation]. 2014 , 55, 547-60; quiz 561		2
1336	Neuromuscular complications after hematopoietic stem cell transplantation. 2014 , 22, 2337-41		14
1335	Oral and dental late effects in survivors of childhood cancer: a Children's Oncology Group report. 2014 , 22, 2009-19		41

1334	Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission. 2014 , 92, 102-10		7
1333	Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. 2014 , 123, 3832-42		265
1332	Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. 2014 , 99, 644-51		8
1331	Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. 2014 , 27, 137-50		84
1330	Stem cell Transplantation for Eradication of Minimal PANcreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study. 2014 , 14, 168		1
1329	Guidelines on the use of extracorporeal photopheresis. 2014 , 28 Suppl 1, 1-37		169
1328	Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 668-75	4-7	29
1327	Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2062-6	4-7	8
1326	Polymyositis in solid organ transplant recipients receiving tacrolimus. 2014 , 345, 239-43		5
1325	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. 2014 , 49, 1124-6		22
1324	Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1751-7	4-7	13
1323	Recent advances in the management of graft-versus-host disease. 2014 , 99, 1150-7		24
1322	The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation. 2014 , 38, 334-9		5
1321	Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 781-6	4-7	17
1320	Early and late oral features of chronic graft-versus-host disease. 2014 , 36, 43-9		8
1319	Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 58-65	4-7	36
1318	Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1217-23	4-7	28
1317	High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 979-85	4-7	33

1316	Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1048-55	4-7	26
1315	Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 696-704	4-7	83
1314	Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 837-43	4-7	15
1313	Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1089-103	4-7	25
1312	Oral features of graft-versus-host disease. 2014 , 36, 9-11		4
1311	Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 556-63	4-7	27
1310	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. 2014 , 38, 737-43		7
1309	Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 730-4	4-7	16
1308	Extracorporeal photopheresis in acute and chronic graft-versus-host disease. 2014 , 50, 349-57		33
1307	Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. 2014 , 32, 585-91		22
1306	The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1211-6	4-7	38
1305	Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 885-90	4-7	37
1304	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. 2014 , 16, 406-11		9
1303	Genital chronic graft-versus-host disease in females: a cross-sectional study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 806-11	4-7	22
1302	Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. 2014 , 166, 758-66		18
1301	Abdominal complications following hematopoietic stem cell transplantation. 2014 , 34, 396-412		25
1300	Complications of allogeneic hematopoietic stem cell transplantation. 2014 , 32, 349-62		50
1299	CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1440-3	4-7	43

1298	Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1426-34	4-7	19
1297	Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1451-4	4-7	13
1296	Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1537-43	4-7	42
1295	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. 2014 , 123, 3988-98		144
1294	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. 2014 , 123, 786-93		75
1293	Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies. 2014 , 49, 1063-9		15
1292	Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. 2014 , 5, 238-44		14
1291	Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1522-9	4-7	44
1290	Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1677-86	4-7	68
1289	Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. 2014 , 6, 380-90		6
1288	Acute graft-versus-host disease: a bench-to-bedside update. 2014 , 124, 363-73		136
1287	Treatment of chronic graft-versus-host disease with bortezomib. 2014 , 124, 1677-88		60
1286	Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. 2014 , 123, 126-32		132
1285	Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. 2014 , 123, 290-9		77
1284	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. 2014 , 124, 2034-45		145
1283	FFS: an end(point) to our problems in chronic GVHD trials?. 2014 , 124, 1216-7		
1282	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. 2014 , 124, 3817-27		128
1281	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. 2014 , 124, 2306-12		30

1280	Disease severity in chronic graft-versus-host disease: doctors' gut feeling versus biostatistics?. 2014 , 99, 1534-6		1
1279	Advanced sclerosis of the chest wall skin secondary to chronic graft-versus-host disease: a case with severe restrictive lung defect. 2014 , 36, e473-5		
1278	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2014 , CD009759		2
1277	In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2173-2179	4-7	21
1276	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2154-2159	4-7	19
1275	Pediatric hematopoietic cell transplantation. 2014 , 3, 91-101		1
1274	Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. 2015 , 37, e94-e101		5
1273	Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. 2015 , 90, 114-9		19
1272	The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. 2015 , 90, E117-21		17
1271	Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management. 2015 , 45, 702-10		9
1270	Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. 2015 , 55, 1993-2000		21
1269	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2015 , CD009759		2
1268	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. 2015 , 125, 199-205		91
1267	How we treat chronic graft-versus-host disease. 2015 , 125, 606-15		185
1266	Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. 2015 , 125, 3173-82		88
1265	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. 2015 , 125, 2885-92		101
1264	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. 2015 , 125, 3024-31		212
1263	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. 2015 , 100, 970-7		16

1262	The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. 2015 , 7, 1480-502	53
1261	Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. 2015 , 100, 1228-36	16
1260	Laser surgical treatment of chronic graft-versus-host disease (cGvHD)-induced buccal mucosal sclerosis. 2015 , 4,	
1259	Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies. 2014 , 4, 6942	4
1258	Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. 2015 , 100, 275-83	1
1257	Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. 2015 , 10, 94	78
1256	New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. 2015 , 62, 680-6	12
1255	Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission. 2015 , 94, 431-8	4
1254	Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. 2015 , 95, 498-506	28
1253	CIDP-like neuropathies in graft versus host disease. 2015 , 20, 1-6	9
1252	Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. 2015 , 15, 584	44
1251	CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations. 2015 , 48, 41	2
1250	Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 2015 , 90, 1021-6	4
1249	Correlation Between Tear Film Osmolarity and the Disease Score of the International Chronic Ocular Graft-Versus-Host-Disease Consensus Group in Hematopoietic Stem Cell Transplantation Patients. 2015 , 34, 911-6	20
1248	Neuromuscular complications of hematopoietic stem cell transplantation. 2015 , 52, 480-7	13
1247	Oral beclomethasone dipropionate successfully controls gastrointestinal graft-versus-host disease without affecting systemic graft-versus-leukemia effect in blastic phase chronic myeloid leukemia. 2015 , 4, 82-86	
1246	Tissue Renin-Angiotensin System in Lacrimal Gland Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease. 2015 , 34 Suppl 11, S142-52	10
1245	Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation. 2015 , 57, 480-3	0

1244	Post-engraftment blood transfusion and outcomes of bone marrow transplantation. 2015 , 10, 93-99	
1243	Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. 2015 , 37, 523-9	10
1242	Ocular Graft-Versus-Host Disease: A Review. 2015 , 41, 256-61	15
1241	Outcomes of cataract surgery in graft-versus-host disease. 2015 , 34, 506-11	22
1240	A case of upper gingiva carcinoma with chronic graft-versus-host disease after allogeneic bone marrow transplantation. 2015 , 60, 404-7	4
1239	Small airways dysfunction in long-term survivors of pediatric stem cell transplantation. 2015 , 50, 704-12	13
1238	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2015 , CD009898	3
1237	Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. 2015 , 29, 1133-9	15
1236	Extracorporeal photopheresis performed on the CELLEX compared with the UVAR-XTS instrument is more efficient and better tolerated in children with steroid-refractory graft-versus-host disease. 2015 , 62, 1485-8	11
1235	Role of Toll-like receptor 4 signaling in cutaneous chronic graft-versus-host disease. 2015 , 29, 547-54	2
1234	Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. 2015 , 17, 761-7	4
1233	Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation. 2015 , 37, e462-7	8
1232	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. 2015 , 171, 411-6	9
1231	Gene Expression-Based Predictive Models of Graft Versus Host Disease-Associated Dry Eye. 2015 , 56, 4570-81	34
1230	Chronic Cutaneous Graft versus Host Disease Mimicking Warts. 2015 , 27, 90-2	3
1229	Photopheresis extracorporelle. 2015 , 21, 4-9	
1228	Graft-versus-host disease affecting oral cavity. A review. 2015 , 7, e138-45	24
1227	Ocular manifestations of graft-versus-host disease: 10 years' experience. 2015 , 9, 1209-13	23

1226	Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. 2015 , 22, e357-63		3
1225	Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. 2015 , 10, e0117001		8
1224	Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host Disease. 2015 , 10, e0134518		15
1223	Dental treatment in patients with leukemia. 2015 , 2015, 571739		17
1222	SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation. 2015 , 50, 40-5		4
1221	Adult onset dyschomatosis universalis. 2015 , 27, 92-4		
1220	Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. 2015 , 212, 959-67		53
1219	Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. 2015 , 191, 1242-9		70
1218	Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1074-82	4-7	11
1217	Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. 2015 , 94, 1677-88		49
1216	Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. 2015 , 15, 335-40		6
1215	Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. 2015 , 151, 635-7		6
1214	Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1770-5	4-7	46
1213	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. 2015 , 126, 415-22		37
1212	Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1299-307	4-7	118
1211	Meibography and meibomian gland measurements in ocular graft-versus-host disease. 2015 , 50, 961-7		45
1210	Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. 2015 , 151, 23-32		25
1209	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1506-14	4-7	91

1208	Cord blood unit factors influencing transplant outcomes from the Asian multiethnic Singapore Cord Blood Bank. 2015 , 50, 1256-8		1
1207	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. 2015 , 33, 2392-8		38
1206	Antibody- and aptamer-strategies for GvHD prevention. 2015 , 19, 11-20		6
1205	Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. 2015 , 99, 1514-8		27
1204	A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. 2015 , 102, 460-70		7
1203	[Ocular graft-versus-host disease]. 2015 , 112, 1027-38; quiz 1039-40		1
1202	Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study. 2015 , 94, e706		12
1201	Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1687-91	4-7	44
1200	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2106-2114	4-7	44
1199	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2002-7	4-7	30
1198	Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2079-2085	4-7	44
1197	Use of Prosthetic Replacement of the Ocular Surface Ecosystem Scleral Lenses in Patients with Ocular Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2180-2184	4-7	31
1196	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. 2015 , 100, 690-5		23
1195	Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. 2015 , 19, 66-74		20
1194	Biopsy-verified bronchiolitis obliterans and other noninfectious lung pathologies after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 531-8	4-7	33
1193	Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 565-9	4-7	14
1192	In vivo confocal microscopic characterisation of the cornea in chronic graft-versus-host disease related severe dry eye disease. 2015 , 99, 160-5		32
1191	Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. 2015 , 50, 259-65		22

1190	Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 729-37	4.7	29
1189	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 906-12	4.7	26
1188	Successful pregnancy and delivery via in vitro fertilization with cryopreserved and thawed embryo transfer in an acute myeloid leukemia patient after allogeneic bone marrow transplantation. 2015 , 101, 417-20		3
1187	2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 387-8	4.7	38
1186	CD161(+) T cells as predictive markers for acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 421-8	4.7	14
1185	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 780-92	4.7	87
1184	NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 589-603	4.7	165
1183	Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 860-5	4.7	13
1182	Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT. 2015 , 50, 289-95		12
1181	Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. 2015 , 90, 392-9		14
1180	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 373-8	4.7	17
1179	Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions—a retrospective multicenter analysis from the German Cooperative Transplant Study Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 453-60	4.7	125
1178	Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 460-7	4.7	11
1177	Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning. 2015 , 29, 124-33		7
1176	Adoptive therapy with donor lymphocyte infusion after allogeneic hematopoietic SCT in pediatric patients. 2015 , 50, 51-5		2
1175	CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 250-8	4.7	32
1174	Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. 2015 , 159, 519-27.e1		26
1173	Oral manifestations compatible with chronic graft-versus-host disease in patients with Fanconi anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 275-80	4.7	9

1172	Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 342-9	4-7	16
1171	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. 2015 , 17, 473-86		112
1170	Oral complications and dental care in children with acute lymphoblastic leukaemia. 2015 , 44, 483-9		24
1169	Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. 2015 , 135, 988-997.e6		91
1168	Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients. 2015 , 50, 225-31		9
1167	Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. 2015 , 50, 679-84		13
1166	Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1020-8	4-7	9
1165	Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components. 2015 , 23, 2561-7		5
1164	Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. 2015 , 50, 968-77		49
1163	A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis. 2015 , 102, 144-6		8
1162	Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1127-31	4-7	26
1161	Elevated level of HSPA1L mRNA correlates with graft-versus-host disease. 2015 , 32, 188-94		4
1160	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. 2015 , 50, 511-6		6
1159	Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants. 2015 , 56, 2348-57		30
1158	Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease. 2015 , 253, 901-7		11
1157	Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients. 2015 , 101, 505-13		10
1156	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. 2015 , 8, 4		29
1155	Hematopoietic stem cell transplantation for infantile osteopetrosis. 2015 , 126, 270-6		65

1154	Chronic Graft-Versus-Host Disease. 2015 , 245-258		
1153	Defects in regulatory T cells due to CD28 deficiency induce a qualitative change of allogeneic immune response in chronic graft-versus-host disease. 2015 , 194, 4162-74		6
1152	An Update on Neonatal and Pediatric Conjunctivitis. 2015 , 3, 158-169		4
1151	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2115-2122	4-7	21
1150	Functional hyposplenism after hematopoietic stem cell transplantation. 2015 , 50, 1343-7		6
1149	Chronic GvHD-associated serositis and pericarditis. 2015 , 50, 1098-104		15
1148	Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis. 2015 , 2, e297-305		14
1147	Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1083-90	4-7	39
1146	Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1973-80	4-7	22
1145	Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease. 2015 , 122, 1669-74		43
1144	The role of extracorporeal photopheresis in chronic graft-versus-host disease. 2015 , 52, 157-61		5
1143	Lung transplantation and extracorporeal photopheresis: The answer to bronchiolitis obliterans?. 2015 , 52, 162-6		7
1142	Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1839-45	4-7	17
1141	Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1641-5	4-7	34
1140	The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. 2015 , 102, 357-63		6
1139	Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. 2015 , 50, 1250-2		10
1138	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. 2015 , 29, 2062-8		360
1137	Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. 2015 , 50, 100-5		42

1136	High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. 2015 , 21, 4312-20		6
1135	Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning. 2015 , 50, 829-33		1
1134	Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. 2015 , 50, 1286-92		8
1133	Animal models of systemic sclerosis. 2015 , 21, 2365-79		12
1132	Interferon- β : A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1939-47	4-7	44
1131	Serum Krebs Von Den Lungen-6 as a Biomarker for Early Detection of Bronchiolitis Obliterans Syndrome in Children Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1524-8	4-7	11
1130	Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1223-9	4-7	10
1129	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1425-30	4-7	9
1128	Tear Osmolarity and Ocular Surface Parameters as Diagnostic Markers of Ocular Graft-Versus-Host Disease. 2015 , 160, 143-9.e1		23
1127	HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1646-52	4-7	66
1126	Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. 2015 , 50, 1180-6		13
1125	Symptoms, Cytokines, and Quality of Life in Patients Diagnosed with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. 2015 , 42, 265-75		21
1124	Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis. 2015 , 50, 566-72		3
1123	Very late-onset reversible cardiomyopathy in patients with chronic GvHD. 2015 , 50, 870-2		1
1122	Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 900-5	4-7	18
1121	Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. 2015 , 29, 636-46		132
1120	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 920-5	4-7	26
1119	A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 646-52	4-7	36

1118	Cytokines in Graft-versus-Host Disease. 2015 , 194, 4604-12		112
1117	Association between Plasma Endothelin-1, Transforming Growth Factor- β Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 948-53	4-7	
1116	Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 799-808	4-7	18
1115	Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Soci� Franise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1452-9	4-7	8
1114	Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 640-5	4-7	21
1113	Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only. 2015 , 94, 1311-8		15
1112	Quantitative computed tomography assessment of graft-versus-host disease-related bronchiolitis obliterans in children: A pilot feasibility study. 2015 , 25, 2931-6		7
1111	Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. 2015 , 23, 1615-22		9
1110	The clinical course of anesthetic induction in lung transplant recipients with pulmonary complications after hematopoietic stem cell transplantation. 2015 , 29, 562-9		1
1109	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. 2015 , 101, 438-51		17
1108	CD24(hi)CD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. 2015 , 125, 1830-9		108
1107	Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders. 2015 , 6, 449-58		22
1106	Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. 2015 , 125, 3193-201		38
1105	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 926-33	4-7	33
1104	Oral disease profiles in chronic graft versus host disease. 2015 , 94, 547-54		30
1103	Atypical manifestations of graft-versus-host disease. 2015 , 72, 690-5		24
1102	Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning. 2015 , 21, 3131-9		25
1101	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1167-87	4-7	128

1100	Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation. 2015 , 34, 243-7	36
1099	Safety and Outcomes of Extracorporeal Photopheresis With the Therakos Cellex System for Graft-Versus-Host Disease in Pediatric Patients. 2015 , 37, 209-14	13
1098	Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. 2015 , 92, S25-32	21
1097	Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. 2015 , 194, 3697-712	32
1096	JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications. 2015 , 50, 984-91	13
1095	State-of-the-art acute and chronic GVHD treatment. 2015 , 101, 452-66	47
1094	Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations. 2015 , 35, 477-484	6
1093	Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. 2015 , 33, 807-18	31
1092	Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life. 2015 , 51, 944-9	20
1091	A review of graft versus host disease. 2014 , 3, 103-113	
1090	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. 2015 , 116, 287-93	6
1089	Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1576-82	4-7 16
1088	A cross-sectional study on vision-related quality of life in patients with ocular GvHD. 2015 , 50, 1224-6	8
1087	Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. 2015 , 94, 1891-7	10
1086	Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead. 2015 , 10, 183-91	12
1085	Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. 2015 , 50, 106-12	12
1084	Characteristic patterns of relapse after allogeneic hematopoietic SCT for adult T-cell leukemia-lymphoma: a comparative study of recurrent lesions after transplantation and chemotherapy by the Nagasaki Transplant Group. 2015 , 50, 585-91	3
1083	A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants. 2015 , 168, 874-81	5

1082	Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. 2015 , 169, 719-25		30
1081	Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation. 2015 , 169, 737-45		18
1080	Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. 2015 , 17, 250-8		26
1079	Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. 2015 , 50, 865-7		8
1078	Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease. 2015 , 135, 999-1006		23
1077	Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. 2015 , 4, 113-126		12
1076	Non-infectious pulmonary complications of hematopoietic stem cell transplantation. 2014 , 3, 133-146		4
1075	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. 2015 , 50, 1293-1298		12
1074	[Clinical Signs of Ocular Graft-versus-Host Disease]. 2015 , 232, 647-51		2
1073	Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1963-72	4-7	30
1072	Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. 2015 , 55, 736-47		18
1071	Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. 2015 , 94, 1727-32		12
1070	[Non-Invasive Diagnosis of Ocular Graft-versus-Host Disease]. 2015 , 232, 652-7		1
1069	Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. 2015 , 50, 1487-9		5
1068	Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 50, 1459-64	4-7	102
1067	Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. 2015 , 50, 1459-64		31
1066	Is peripheral blood or bone marrow a better source of stem cells for transplantation in cases of HLA-matched unrelated donors? A meta-analysis. 2015 , 96, 20-33		9
1065	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2160-2166	4-7	23

1064	Numerical impairment of nestin(+) bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML. 2015 , 50, 1453-8		8
1063	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. 2015 , 33, 3152-61		165
1062	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1761-9	4.7	103
1061	Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. 2015 , 94, 1899-905		31
1060	A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies. 2015 , 50, 1519-25		8
1059	Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model. 2015 , 135, 2385-2393		18
1058	A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma. 2015 , 15, 655-63		3
1057	Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. 2015 , 50, 1217-23		42
1056	Identification and validation of biomarkers associated with acute and chronic graft versus host disease. 2015 , 50, 1563-71		42
1055	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. 2015 , 8, 84		106
1054	Unrelated hematopoietic stem cell transplantation in the pediatric population: single institution experience. 2015 , 37, 236-41		1
1053	Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy. 2015 , 18, 457-66		21
1052	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1985-93	4.7	35
1051	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. 2015 , 100, 1477-85		26
1050	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. 2015 , 26, 2490-5		63
1049	Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. 2015 , 29, 948-54		29
1048	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
1047	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 389-401.e1	4.7	1187

1046	Phototherapy for the treatment of cutaneous graft versus host disease. 2015 , 56, 93-9	12
1045	Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. 2015 , 24, 253-63	32
1044	Liver disease after hematopoietic cell transplantation in adults. 2015 , 29, 8-15	15
1043	Achievement of early complete donor chimerism in CD25+ activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation. 2015 , 43, 4-13.e1	2
1042	Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). 2015 , 50, 253-8	6
1041	Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 288-92	4.7 36
1040	Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 159-64	4.7 33
1039	Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. 2015 , 50, 3-9	35
1038	Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies. 2015 , 62, 257-73	7
1037	Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. 2015 , 50, 127-33	25
1036	Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation. 2015 , 62, 522-8	18
1035	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. 2015 , 21, 2020-8	69
1034	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 281-7	4.7 16
1033	Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. 2015 , 50, 449-51	6
1032	A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. 2015 , 50, 62-7	41
1031	Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. 2015 , 56, 663-70	13
1030	Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score. 2014 , 4, 6680	11
1029	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. 2015 , 29, 137-44	142

1028	Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. 2015 , 94, 275-82	29
1027	Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 2015 , 168, 405-12	33
1026	A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 119-29	4-7 27
1025	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. 2015 , 56, 1058-65	11
1024	Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML. 2015 , 50, 74-81	21
1023	Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. 2016 , 34, 9-16	18
1022	Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. 2016 , 1, 152-159	12
1021	Oral Lichenoid and Lichen Planus-like Lesions. 2016 , 5, 34-39	5
1020	Changes in Ocular Surface after Hematopoietic Stem Cell Transplantation. 2016 , 57, 1706	1
1019	The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation. 2016 , 57, 16-28	8
1018	Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation. 2016 , 57, 255-65	
1017	Chronic graft-vs-host disease in 2016: a major challenge and an opportunity. 2016 , 57, 1-3	2
1016	Vitamin D levels and their associations with survival and major disease outcomes in a large cohort of patients with chronic graft-vs-host disease. 2016 , 57, 276-86	7
1015	Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. 2016 , 57, 247-54	8
1014	Graft-versus-host disease management. 2016 , 117, 388-96	4
1013	The Gut Microbiota and Immune System Relationship in Human Graft-versus-Host Disease. 2016 , 8, e2016025	26
1012	Biology of chronic graft--host disease: Immune mechanisms and progress in biomarker discovery. 2016 , 6, 608-619	18
1011	Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. 2016 , 7, 13260-13264	50

1010	Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model. 2016 , 57, 746-58	58
1009	Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors. 2016 , 20, 414-417	
1008	Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia. 2016 , 63, 595-600	
1007	Bacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre Experience. 2017 , 9, e2017036	6
1006	Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?. 2016 , 57, 239-46	2
1005	Survival Benefit of Intravenous Busulfan (120 mg/M2) and Fludarabine Myeloablative Regimen for Treatment of Myeloid Malignancies. 2016 , 06,	
1004	Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters. 2016 , 57, 266-75	4
1003	Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?. 2016 , 57, 6-15	8
1002	Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation. 2016 , 2016, 5143071	9
1001	Haploidentical hematopoietic stem cell transplantation without total body irradiation for pediatric acute leukemia: a single-center experience. 2016 , 9, 2557-63	2
1000	High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. 2016 , 57, 229-38	14
999	Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. 2016 , 62 Suppl 1, 44-50	15
998	miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. 2016 , 7, 56	19
997	The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. 2016 , 7, 333	24
996	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. 2016 , 7, 595	26
995	Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. 2016 , 11, e0158242	13
994	Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. 2016 , 11, e0167129	2
993	The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. 2016 , 63, 743-51	8

992	Obliterative Bronchiolitis. 2016 , 100, 272-83		29
991	Simultaneous Quantification of the 8 Human Herpesviruses in Allogeneic Hematopoietic Stem Cell Transplantation. 2016 , 100, 1363-70		1
990	PROSE Treatment for Ocular Chronic Graft-Versus-Host Disease as a Clinical Network Expands. 2016 , 42, 262-6		19
989	Late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments. 2016 , 18, 492-503		9
988	Dry Eye Disease Is Already Present in Hematological Patients Before Hematopoietic Stem Cell Transplantation. 2016 , 35, 638-43		22
987	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 , 173, 96-104		43
986	Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. 2016 , 31, 347-52		14
985	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. 2016 , 34, 297-308		30
984	Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT. 2016 , 97, 232-8		4
983	Quality of Life After Hematopoietic Stem Cell Transplantation in Pediatric Survivors: Comparison With Healthy Controls and Risk Factors. 2016 , 39, 502-509		10
982	Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations. 2016 , 172, 937-46		14
981	Dendritic cell chimerism in oral mucosa of transplanted patients affected by graft-versus-host disease. 2016 , 45, 127-35		1
980	Evaluation of engraftment syndrome in children following full-matched related donor hematopoietic stem cell transplantations. 2016 , 20, 581-9		7
979	Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. 2016 , 91, 883-7		2
978	Acute myofascitis as a manifestation of chronic graft-versus-host disease. 2016 , 53, 327-9		1
977	T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1861-1866	4.7	9
976	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1801-1807	4.7	6
975	Optimal Outcomes in Young Class 3 Patients With Thalassemia Undergoing HLA-Identical Sibling Bone Marrow Transplantation. 2016 , 100, 925-32		31

974	Eruptive angiokeratomas and porokeratosis in the setting of sclerodermatous graft-vs.-host disease. 2016 , 43, 516-519	1
973	Treatment of overlap cutaneous graft-versus-host disease with combination therapy of extracorporeal photopheresis and alemtuzumab. 2016 , 55, 335-8	
972	Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. 2016 , 22, 235-40	3
971	Infections and neutrophils in the pathogenesis of bronchiolitis obliterans syndrome in children after allogeneic stem cell transplantation. 2016 , 20, 303-6	2
970	Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantation. 2016 ,	
969	Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients. 2016 , 4, 667-671	3
968	Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease. 2016 , 55, 2265-70	3
967	Hematopoietic Stem Cell Transplantation Nephropathy Associated with Chronic Graft-versus-Host Disease without Extrarenal Involvement. 2016 , 55, 2837-2842	2
966	Air-leak Syndrome by Pleuroparenchymal Fibroelastosis after Bone Marrow Transplantation. 2016 , 55, 105-11	11
965	Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis. 2016 , 55, 3351-3356	
964	Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. 2017 , 101, 322-326	22
963	The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 2016 ,	
962	Dichotomy in pulmonary graft-versus-host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation. 2016 , 48, 1807-1810	12
961	Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant. 2016 , 12, 2078-2082	16
960	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. 2016 , 101, 499-505	26
959	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. 2016 , 128, 2350-2358	33
958	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. 2016 , 101, e465-e468	32
957	Indiscernible Benefit of Double-Unit Umbilical Cord Blood Transplantation in Children: A Single-Center Experience From Hong Kong. 2016 , 25, 1277-86	4

956	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. 2016 , 100, e147-e155		30
955	A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGVHD. 2016 , 38, e295-e297		1
954	Late-onset acute GVHD: clues for endothelial GVHD. 2016 , 128, 2282-2283		1
953	Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1257-1263	4-7	42
952	Development, preliminary usability and accuracy testing of the EBMT 'eGVHD App' to support GVHD assessment according to NIH criteria-a proof of concept. 2016 , 51, 1062-5		12
951	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1080-1086	4-7	12
950	Sexual function 1-year after allogeneic hematopoietic stem cell transplantation. 2016 , 51, 833-40		16
949	Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis	4-7	112
948	A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 682-689	4-7	7
947	Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. 2016 , 101, 644-52		17
946	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cyto-reduction with Clofarabine, Melphalan, and Thiotepea. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1449-1454	4-7	6
945	Case-Based Inpatient Pediatric Dermatology. 2016 ,		0
944	Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1073-1079	4-7	10
943	Disminuci3n de mortalidad en hemopat3as malignas con un nuevo m3todo de acondicionamiento para trasplante alog3nico mieloablativo. 2016 , 15, 16-21		
942	A short view of chronic graft-vs-host disease. 2016 , 30, 4-5		
941	Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. 2016 , 47, 22-5		7
940	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. 2016 , 95, 625-35		11
939	Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?. 2016 , 54, 30-4		13

938	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1440-1448	4-7	36
937	Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. 2016 , 51, 1050-61		33
936	Restricted mouth opening in chronic graft-versus-host disease. 2016 , 121, 201-2		3
935	Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD. 2016 , 95, 493-9		8
934	Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 925-31	4-7	22
933	Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 815-24	4-7	18
932	Graft-versus-host Disease After Intestinal or Multivisceral Transplantation: A Scandinavian Single-center Experience. 2016 , 48, 185-90		9
931	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. 2016 , 34, 1855-63		57
930	New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. 2016 , 51, 1256-8		
929	Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1403-1409	4-7	35
928	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. 2016 , 101, 634-43		26
927	Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD. 2016 , 104, 117-24		6
926	Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1517-1524	4-7	9
925	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. 2016 , 16, 466-471.e1		29
924	Haploidentical HCT using an T-cell-depleted graft with targeted T(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI. 2016 , 51, 1217-22		12
923	[Non-Infectious Conjunctiva Diseases]. 2016 , 233, 547-64		0
922	Nicht infektiöse Bindehauterkrankungen. 2016 , 6, 71-86		
921	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. 2016 , 127, 160-6		35

920	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. 2016 , 127, 2249-60		54
919	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. 2016 , 128, 72-81		19
918	Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. 2016 , 127, 1828-35		35
917	Alloantigen presentation and graft-versus-host disease: fuel for the fire. 2016 , 127, 2963-70		38
916	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. 2016 , 128, 130-7		132
915	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2226-2234	4-7	8
914	Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation. 2016 , 44, 917-23		2
913	Cord-Blood Transplantation in Patients with Minimal Residual Disease. 2016 , 375, 944-53		247
912	Comparison of Donor Sources in Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Nationwide Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2226-2234	4-7	11
911	Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. 2016 , 136, 193-200		9
910	Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease. 2016 , 140, 570-7		10
909	Management of Graft-Versus-Host Disease. 2016 , 1, 419-433		
908	Guillain-Barré Syndrome after allogeneic bone marrow transplantation: Case report and literature review. 2016 , 4, 52-55		6
907	Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. 2016 , 197, 3490-3503		30
906	Influenza and Parainfluenza Infection in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. 2016 , 563-580		
905	Special Considerations for Long-Term Survivors After Hematopoietic Stem Cell Transplantation. 2016 , 951-962		
904	Risks and Epidemiology of Infections After Hematopoietic Stem Cell Transplantation. 2016 , 81-99		4
903	Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors. 2016 , 33, 347-358		3

902	Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis. 2016 , 56, 3081-3085		2
901	Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience. 2016 , 38, 314-319		1
900	Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?. 2016 , 51, 1573-1578		6
899	The Total Body Irradiation Schedule Affects Acute Leukemia Relapse After Matched T Cell-Depleted Hematopoietic Stem Cell Transplantation. 2016 , 96, 832-839		3
898	Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1816-1822	4-7	21
897	Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1997-2002	4-7	14
896	Oral Complications of Hematopoietic Cell Transplantation. 2016 , 1242-1258		1
895	Delayed Non-malignant Complications After Hematopoietic Cell Transplantation. 2016 , 1266-1276		
894	The Pathophysiology of Graft-versus-Host Disease. 2016 , 146-155		4
893	Pathology of Hematopoietic Cell Transplantation. 2016 , 292-332		3
892	Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy]. 2016 , 1020-1039		1
891	Lung Injury Following Hematopoietic Cell Transplantation. 2016 , 1156-1172		1
890	Nutrition Support of the Hematopoietic Cell Transplant Recipient. 2016 , 1216-1226		1
889	Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2019-2024	4-7	10
888	Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. 2016 , 51, 1588-1593		32
887	Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1781-1791	4-7	44
886	An atypical response following intraoral intralesional steroid therapy. 2016 , 9, 58-61		
885	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. 2016 , 51, 1599-1601		32

884	Attenuation of graft-versus-host-disease in NOD scid IL-2R β ($-/-$) (NSG) mice by ex vivo modulation of human CD4(+) T cells. 2016 , 89, 803-15		11
883	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. 2016 , 59, 1139-1148		9
882	Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2047-2055	4-7	36
881	Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies. 2016 , 77, 861-868		6
880	A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2011-2018	4-7	19
879	Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. 2016 , 13, 1932-1939		44
878	Spirometry States the Obvious: Recognizing Bronchiolitis Obliterans Syndrome Early after Hematopoietic Cell Transplantation. 2016 , 13, 1883-1884		2
877	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. 2016 , 101, 1417-1425		41
876	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. 2016 , 5, e1250992		15
875	ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation. 2016 , 30, 1457-1465		8
874	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. 2016 , 128, 1528-31		34
873	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. 2016 , 9, 87		41
872	Pathology of Transplantation. 2016 ,		1
871	Hematopoietic Stem Cell Transplantation. 2016 , 401-449		5
870	Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2065-2076	4-7	22
869	Early outcomes of lung transplantation for bronchiolitis obliterans syndrome after allogeneic haematopoietic stem cell transplantation: a single-centre experience. 2016 , 23, 914-918		4
868	Genetic risk factors for sclerotic graft-versus-host disease. 2016 , 128, 1516-24		12
867	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. 2016 , 127, 2489-97		71

866	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. 2016 , 127, 3082-91	57
865	Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis. 2016 , 104, 628-635	20
864	Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation. 2016 , 36, 783-788	10
863	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. 2016 , 375, 143-53	365
862	Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation. 2016 , 34, 2843-50	89
861	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. 2016 , 139, 2106-15	35
860	Deadly Dermatologic Diseases. 2016 ,	1
859	Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. 2016 , 9, 72	18
858	Graft-Versus-Host Disease. 2016 , 247-250	
857	Lower incidence of acute GVHD is associated with the rapid recovery of CD4CD25CD45RA regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. 2016 , 5, e1242546	9
856	Lymphoid malignancy is a risk factor for CMV infection in the early phase of allogeneic stem cell transplantation.. 2016 , 5, 41-50	1
855	Late effects and QOL after stem cell transplantation in childhood. 2016 , 5, 51-63	
854	Role of Ultrasound in Complications of Hematopoetic Stem Cell Transplantation. 2016 , 32, 212-23	2
853	Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response. 2016 , 95, e5356	4
852	Acral verruca-like presentation of chronic graft-vs.-host disease. 2016 , 43, 236-41	2
851	Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis. 2016 , 96, 425-34	10
850	Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center. 2016 , 51, 1354-1360	16
849	High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD. 2016 , 51, 1513-1517	10

848	Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1654-1663	4-7	28
847	Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. 2016 , 51, 1350-1353		13
846	Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 292-299	4-7	11
845	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1431-1439	4-7	18
844	Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver: An Update. 2016 , 145, 591-603		30
843	Sonographic Appearance of the Gallbladder in the Allogeneic Hematopoietic Stem Cell Transplant Population. 2016 , 35, 1403-9		4
842	Superior Limbic Keratoconjunctivitis-like Inflammation in Patients with Chronic Graft-Versus-Host Disease. 2016 , 14, 393-400		29
841	High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis. 2016 , 51, 1518-1521		8
840	A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1664-1670	4-7	9
839	The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center. 2016 , 51, 1496-1498		9
838	Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. 2016 , 34, 17-21		4
837	Graft-versus-host disease in paediatric solid organ transplantation: A review of the literature. 2016 , 20, 607-18		25
836	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. 2016 , 18, 216-26		12
835	Comparable outcomes between younger (?40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. 2016 , 51, 1456-1463		28
834	Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?. 2016 , 173, 905-17		10
833	OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. 2016 , 96, 27-35		36
832	Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome. 2016 , 32, 32-8		6
831	Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. 2016 , 49, 567-74		28

830	Formulation of budesonide mouthwash for the treatment of oral chronic graft-versus-host disease. 2016 , 22, 82-5		2
829	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. 2016 , 34, 1112-21		391
828	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 449-55	4-7	71
827	Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 2016 , 196, 1400-11		24
826	Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. 2016 , 103, 155-64		15
825	Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature. 2016 , 135, 1-10		21
824	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 862-8	4-7	26
823	The Systemic Metabolic Profile Early after Allogeneic Stem Cell Transplantation: Effects of Adequate Energy Support Administered through Enteral Feeding Tube. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 380-391	4-7	5
822	Partially CD3-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 493-501	4-7	2
821	Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. 2020 , 42, 145-151		3
820	Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia. 2020 , 189, 146-152		19
819	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2299-2305	4-7	2
818	Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. 2020 , 68, 131-137		1
817	Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 2020 , 10, 572918		2
816	Mimickers of pulmonary lymphoma. 2020 , 37, 283-295		4
815	Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2014-2017	4-7	7
814	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2075-2081	4-7	4
813	The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. 2020 , 4, 4812-4821		4

812	Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study. 2020 , 61, 969-976		3
811	Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study. 2020 , 40, 5909-5917		3
810	Topical Corticosteroids a Viable Solution for Oral Graft Versus Host Disease? A Systematic Insight on Randomized Clinical Trials. 2020 , 56,		
809	Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. 2020 , 4, 3102-3108		11
808	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1446-1451	4-7	9
807	Histopathological Grading of Oral Mucosal Chronic Graft-versus-Host Disease: Large Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1971-1979	4-7	1
806	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). 2020 , 38, 2993-3002		122
805	Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2027-2033	4-7	1
804	How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft--Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. 2020 , 11, 583564		2
803	Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease. 2020 , 12,		11
802	Preemptive interferon- β treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. 2020 , 10, 20148		3
801	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. 2020 , 172, 229-239		48
800	Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. 2020 , 24, e13789		0
799	Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1861-1867	4-7	1
798	Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan. 2020 , 11, 1617		2
797	Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2082-2088	4-7	2
796	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1655-1662	4-7	2
795	Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 10, 1043-1061		2

794	Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. 2020 , 112, 510-523	6
793	Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT. 2020 , 99, 2927-2937	
792	Impact of Clostridioides difficile infection on the outcome of patients receiving a hematopoietic stem cell transplantation. 2020 , 99, 428-436	2
791	CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease. 2020 , 104, 2354-2359	1
790	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. 2020 , 11, 567210	6
789	Supportive Care Strategies. 2020 ,	
788	Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. 2020 , 4, 5311-5321	2
787	Application of metagenomic next-generation sequencing technology for difficult lung lesions in patients with haematological diseases.. 2020 , 9, 5245-5254	0
786	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. 2020 , 4, 3913-3925	20
785	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. 2020 , 13, 1119-1130	1
784	Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. 2020 , 5, 67	3
783	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. 2020 , 4, 3977-3989	30
782	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. 2020 , 4, 3900-3912	12
781	Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. 2020 , 99, 2939-2945	
780	Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease Classification. 2020 , 9, 3	5
779	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. 2020 , 4, 3302-3310	6
778	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. 2020 , 4, 3822-3828	1
777	Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 12,	4

776	Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 158, e89-e91		3
775	Effect of donor age on adult unrelated donor hematopoietic cell transplant outcome: the Australian experience. 2020 ,		
774	Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin. 2020 , 29, 963689720976567		2
773	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. 2020 , 4, 6064-6076		7
772	Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease. 2020 , 11, 602547		4
771	New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. 2020 , 11, 578314		16
770	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. 2020 , 99, 1341-1350		5
769	Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1303-1311	4-7	3
768	A study of bacterial profile and antibiotic susceptibility pattern found in drinking water at district Mansehra, Pakistan. 2020 , 10, 5435-5439		2
767	Application of infrared thermography to determine the correlation between skin temperature and onset of graft versus host disease in patients after bone marrow transplantation: A preliminary study. 2020 , 156, 106350		
766	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. 2020 , 55, 1560-1569		2
765	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. 2020 , 55, 2160-2169		7
764	Differential microRNAs expression in acute graft-versus-host disease as potential diagnostic biomarkers. 2020 , 55, 2339-2342		1
763	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1439-1445	4-7	8
762	Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation. 2020 , 146, 2143-2152		3
761	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1575-1580	4-7	12
760	Management and long-term consequences of genital graft versus host disease following hematopoietic stem cell transplantation. 2020 , 55, 2234-2243		1
759	Dental follow-up and maintenance index: the development of a novel multidisciplinary protocol. 2020 , 6, e03954		0

758	Inflammatory bowel disease-like conditions after organ transplantation. 2020 , 427-438		
757	Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. 2020 , 99, 1855-1862		5
756	Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach. 2020 , 11, 141-162		5
755	Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. 2020 , 9, 1190-1202		19
754	A Prospective Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1627-1634	4-7	4
753	Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL. 2020 , 12, 1758835920927605		3
752	Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease. 2020 , 146, 2967-2978		2
751	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. 2020 , 95, 1135		1
750	Calcinosis Cutis Associated with Chronic Sclerodermoid Graft versus Host Disease: A Case and Review of the Literature. 2020 , 2020, 9250923		0
749	Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. 2020 , 40, 93-104		12
748	Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score. 2020 , 55, 1966-1974		3
747	Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients. 2020 , 25, 125-133		1
746	Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis. 2020 , 13, 565-575		5
745	European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation. 2020 , 83, 238-244		0
744	Ruxolitinib for the treatment of graft-versus-host disease. 2020 , 16, 347-359		5
743	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. 2020 , 61, 1678-1687		3
742	Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases. 2020 , 55, 2017-2025		5
741	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1288-1297	4-7	7

740	Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. 2020 , 11, 1338		25
739	CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. 2020 , 11, 254		5
738	Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1923-1929	4-7	13
737	Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1855-1860	4-7	6
736	Hematopoietic stem cell transplantation for primary immune deficiencies. 2020 , 1175-1214		
735	Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. 2020 , 55, 1570-1579		3
734	Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients. 2020 , 12,		6
733	Protective Effects of Cytomegalovirus DNA Copies ≥ 1000 /mL for AML Patients in Complete Remission After Single Cord Blood Transplantation. 2020 , 13, 373-383		0
732	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. 2020 , 6, 696-705		10
731	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. 2020 , 55, 1736-1743		6
730	Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. 2020 , 55, 1754-1762		11
729	Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. 2020 , 55, 1379-1387		15
728	Diagnostic and Prognostic Biomarkers for Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 47, E35-E43		
727	Comparison of melphalan- And busulfan-based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia. 2020 , 24, e13672		3
726	Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients. 2020 , 55, 1255-1263		1
725	Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome. 2020 , 55, 1595-1603		2
724	The role of serum uric acid in the prediction of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. 2020 , 34, e23271		14
723	Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation. 2020 , 99, 591-598		1

722	Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. 2019 , 10, 3027		5
721	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. 2020 , 22, 158-165		8
720	Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. 2020 , 67, e28190		10
719	Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD). 2020 , 18, 298-304		12
718	Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation in children. 2020 , 55, 631-637		4
717	Cancer Rehabilitation in the Pediatric and Adolescent/Young Adult Population. 2020 , 36, 150984		7
716	Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF- β and p-SMAD Pathway. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 823-834	4-7	14
715	Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. 2020 , 34, e13810		9
714	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. 2020 , 55, 1147-1160		11
713	Proteomics for hematopoietic stem cell transplantation. 2020 , 17, 201-206		1
712	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1452-1458	4-7	2
711	A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. 2020 , 99, 2649-2657		1
710	Ocular Graft-Versus-Host Disease Topic Review. 2020 , 8, 36-43		2
709	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1332-1341	4-7	17
708	Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. 2020 , 34, 1229-1240		27
707	Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best perceived in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. 2020 , 55, 1847-1850		5
706	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. 2020 , 4, 1656-1669		40
705	The challenge of long-term follow-up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resource-limited countries: A single-center report from Brazil. 2020 , 24, e13691		1

704	CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). 2020 , 95, 892-899	4
703	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. 2020 , 135, 97-107	29
702	Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation. 2020 , 59, 102743	1
701	Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors. 2020 , 57, 445-456	4
700	Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. 2020 , 135, 1287-1298	18
699	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. 2020 , 4, 40-46	3
698	Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. 2020 , 4, 408-419	10
697	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. 2020 , 4, 1242-1249	10
696	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. 2020 , 10, 320	9
695	Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. 2020 , 55, 27-34	1
694	Serum albumin and C-reactive protein as significant predictors of non-relapse mortality in lower gastrointestinal graft-versus-host disease. 2020 , 99, 1111-1119	1
693	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. 2020 , 61, 1996-2002	6
692	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. 2021 , 35, 585-594	9
691	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. 2021 , 106, 1599-1607	6
690	Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. 2021 , 56, 129-136	5
689	Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children : Results of a prospective study on behalf of the German-Austrian-Swiss GVHD Consortium. 2021 , 133, 41-51	1
688	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. 2021 , 56, 38-49	2
687	Late cognitive outcomes among allogeneic stem cell transplant survivors: follow-up data from a 6-year longitudinal study. 2021 , 29, 2621-2630	1

686	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. 2021 , 60, 466-474	1
685	Double-unit unrelated cord blood transplantation for thalassemia major: Comparison with HLA-identical sibling bone marrow transplantation. 2021 , 25, e13901	1
684	Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. 2021 , 27, 67.e1-67.e7	0
683	Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. 2021 , 56, 357-367	2
682	Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. 2021 , 56, 101-109	7
681	Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children. 2021 , 27, 71.e1-71.e12	2
680	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. 2021 , 56, 614-621	1
679	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. 2021 , 62, 399-409	0
678	Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation. 2021 , 27, 82.e1-82.e8	0
677	WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. 2021 , 21, e145-e151	2
676	Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. 2021 , 62, 419-427	2
675	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. 2021 , 56, 1077-1085	1
674	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. 2021 , 41, 414-426	4
673	T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after β_2 cell-depleted hematopoietic stem cell transplantation. 2021 , 56, 900-908	2
672	Myeloablative Versus Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis. 2021 , 37, 472-478	0
671	Human leukocyte antigen disparities reduce relapse after hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A single-center retrospective study from China. 2021 , 25, e13825	0
670	Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. 2021 , 100, 959-968	9
669	High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease. 2021 , 100, 1321-1328	4

668	Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation. 2021 , 18, 905-918	1
667	Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet. 2021 , 27, 173.e1-173.e9	2
666	Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. 2021 , 10, 542-553	4
665	Peri-transplant extracorporeal photopheresis to mitigate GVHD- a pilot clinical trial. 2021 , 56, 980-982	0
664	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. 2021 , 56, 1180-1189	22
663	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. 2021 , 96, 179-187	6
662	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation. 2021 , 27, 327.e1-327.e11	
661	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. 2021 , 100, 209-216	4
660	Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients. 2021 , 113, 145-157	
659	Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. 2021 , 56, 828-840	4
658	Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: Joint model for minimal residual disease. 2021 , 43, 84-92	1
657	Treatment of graft versus host disease with methotrexate after allogeneic hematopoietic stem cell transplantation. 2021 , 19, 109-111	
656	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. 2021 , 137, 896-907	8
655	Chronic graft-versus-host disease in pancreas after kidney transplant recipients - An unrecognized entity. 2021 , 21, 883-888	1
654	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. 2021 , 56, 243-256	3
653	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. 2021 , 100, 789-798	2
652	A Rare Case of Tongue Neoplasia Treated Successfully in a Patient With B-Cell Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 32, e452-e454	1
651	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. 2021 , 5, 584-592	0

650	A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients. 2021 , 35, 617-622	
649	Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation. 2021 , 113, 556-565	2
648	Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. 2021 , 120, 2144-2152	4
647	The Association between Meibomian Gland Atrophy and Corneal Subbasal Nerve Loss in Patients with Chronic Ocular Graft-versus-host Disease. 2021 , 46, 796-801	2
646	Ex Vivo Manipulation of Stem Cell Product. 2021 , 483-498	
645	Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. 2021 , 22,	9
644	Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas. 2021 , 30, 963689721999615	0
643	Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation. 2021 , 147, 2137-2144	2
642	Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. 2021 , 113, 566-575	0
641	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. 2021 , 137, 126-137	14
640	A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. 2021 , 100, 743-752	
639	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. 2021 , 113, 712-722	1
638	Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission. 2021 , 21, e126-e136	1
637	Functional Contributions of Antigen Presenting Cells in Chronic Graft-Versus-Host Disease. 2021 , 12, 614183	1
636	Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. 2021 , 13,	0
635	Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. 2021 , 11, 42	1
634	[Potential of ultrasound in allogeneic stem cell transplantation and transplant-related complications]. 2021 , 59, 336-344	0
633	Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia. 2021 , 56, 1614-1624	9

- 632 Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease. **2021**, 56, 1584-1592
- 631 Profiling Tissue and Biofluid miR-155-5p, miR-155, and miR-146a-5p Expression in Graft vs. Host Disease. **2021**, 12, 639171 0
- 630 The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. **2021**, 27, 448-451 4
- 629 HLA-haploidentical TCR $\alpha\beta$ /CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia. **2021**, 5, 1333-1339 4
- 628 Skin chronic GVHD. **2021**, 140-165
- 627 Posttransplant Considerations in Gender, Reproductive, and Sexual Health. **2021**, 198-210
- 626 Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. **2021**, 5, 1360-1368 7
- 625 Thymopoiesis, Alterations in Dendritic Cells and Tregs, and Reduced T Cell Activation in Successful Extracorporeal Photopheresis Treatment of GVHD. **2021**, 41, 1016-1030 2
- 624 G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. **2021**, 11, 631625 2
- 623 Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview. **2021**, 57, 3
- 622 A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. **2021**, 100, 2095-2103
- 621 Graft-versus-host disease and late effects after hematopoietic stem cell transplantation. **2021**, 73-79
- 620 Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. **2021**, 27, 478.e1-478.e5 2
- 619 Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation. **2021**, 113, 877-883 0
- 618 Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). **2021**, 35, e14255 1
- 617 Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. **2021**, 62, 2177-2183
- 616 Management of oral and dental complications. **2021**, 176-182
- 615 Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. **2021**, 10, 2

614	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. 2021 , 113, 1405-1414	1
613	Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease. 2021 , 23, 30	4
612	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. 2021 , 100, 2339-2350	3
611	Successful Allogeneic Peripheral Blood Stem Cell Transplantation in 4 Wiskott-Aldrich Syndrome Patients. 2021 ,	0
610	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. 2021 , 27, 328.e1-328.e6	
609	The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen. 2021 , 100, 1879-1889	1
608	Continuation of systemic treatments and outcomes for patients with chronic graft-versus-host disease in the USA. 2021 , 13, 387-395	
607	Inflammatory Conditions of the Colon. 2021 , 235-305	
606	Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study. 2021 , 56, 2088-2096	0
605	Intrabone infusion for allogeneic umbilical cord blood transplantation in children. 2021 , 56, 1937-1943	
604	Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. 2021 , 56, 1953-1963	2
603	B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease. 2021 , 62, 154-164	0
602	Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. 2021 ,	3
601	Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. 2021 , 56, 1964-1970	1
600	Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. 2021 , 12, 605766	6
599	Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years. 2021 , 100, 2363-2373	0
598	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). 2021 , 96, 834-845	0
597	Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review. 2021 , 13,	1

596	Outcomes of allogeneic transplantation for hemoglobin Bart's hydrops fetalis syndrome in Hong Kong. 2021 , 25, e14037	2
595	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. 2021 , 56, 2355-2366	6
594	Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. 2021 , 56, 2248-2258	2
593	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. 2021 , 62, 2747-2754	2
592	Selection Criteria for Lung Transplantation: Controversies and New Developments. 2021 , 42, 329-345	
591	Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. 2021 , 10, 3165-3176	1
590	Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients. 2021 , 27, 607-614	0
589	Alloimmune Myositis as Paraneoplastic Complication of an Oral Squamous Cell Carcinoma After Severe Chronic Graft vs Host Disease or a Manifestation of Chronic Graft vs Host Disease? A Case Report and Literature Discussion. 2021 , 53, 1365-1368	
588	Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. 2021 , 68, e29087	1
587	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. 2021 , 56, 2231-2240	1
586	A bi-centric experience of extracorporeal carbon dioxide removal (ECCO R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation. 2021 , 45, 903-910	2
585	The safety and effectiveness of donor memory T lymphocyte infusions after hematopoietic stem cell transplantation with ab T cell depletion platform in children with acute leukemia. 2021 , 20, 12-28	
584	Ophthalmologic findings and complications before and after hematopoietic stem cell transplantation: single-center study. 2021 , 41, 2533-2538	0
583	A Roadmap of Cancer: From the Historical Evidence to Recent Salivary Metabolites-based Nanobiosensor Diagnostic Devices. 2021 , 8, 27-52	1
582	LMP7 polymorphism may modify the presentation and clinical impact of minor histocompatibility antigens in matched related hematopoietic stem cell transplantation. 2021 , 364, 104329	
581	Diagnostic utility of upper and lower gastrointestinal endoscopy for the diagnosis of acute graft-versus-host disease in children following stem cell transplantation: A 12-year experience. 2021 , 25, e14046	0
580	Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children. 2021 , 1	0
579	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. 2021 , 131,	2

578	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplant. 2021 , 36, 697-710	0
577	Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience. 2021 , 38, 195-203	
576	Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation. 2021 , 107, 393-407	3
575	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. 2021 , 66, 2498-2498	15
574	Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. 2021 ,	1
573	Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission. 2021 , 114, 464-471	0
572	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. 2021 , 134, 1584-1592	0
571	Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease. 2021 , 51, 134-138	1
570	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. 2021 , 107, 517-528	0
569	Steroid-responsive chronic inflammatory demyelinating polyradiculoneuropathy post-hematopoietic stem cell transplantation: a case report and literature review. 2021 , 42, 4793-4799	0
568	On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation. 2021 ,	0
567	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). 2021 , 39, 3318-3327	7
566	A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. 2021 , 1-10	4
565	Transfusions in Aplastic Anemia Patients Cause HLA Alloimmunization: Comparisons of Current and Past Cohorts Demonstrate Progress. 2021 , 27, 939.e1-939.e8	0
564	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. 2021 , 27, 540-544	1
563	Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 27, 949.e1-949.e8	
562	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. 2021 , 56, 2749-2754	
561	T-cell replete haploidentical stem cell transplantation with low dose anti-thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors. 2021 , e1519	

560	Oral white lesion in patients post-hematopoietic stem cell transplantation: a case series demonstrating the diagnostic dilemma. 2021 , 29, 7999-8007	1
559	The disposable bandage soft contact lenses therapy and anterior segment optical coherence tomography for management of ocular graft-versus-host disease. 2021 , 21, 271	0
558	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. 2021 , 11, 705568	0
557	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. 2021 , 27, 619.e1-619.e8	1
556	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. 2021 , 5, 2740-2750	2
555	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). 2021 , 62, 3181-3191	3
554	A retrospective study of acute graft-vs-host disease and its mimickers in the posttransplant period. 2021 ,	
553	Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. 2021 , 48, 100792	14
552	Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease. 2021 , 30, 1814-1819	
551	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. 2021 , 27, 545-557	15
550	A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. 2021 , 27, 928.e1-928.e7	0
549	Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease. 2021 , 27, 925.e1-925.e7	1
548	Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis. 2021 , 42, 525-536	0
547	Impact of anti-anaerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling. 2021 , 23, e13676	
546	A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia. 2021 , 11, 702239	1
545	Early remodeling of the colonic mucosa after allogeneic hematopoietic stem cells transplantation: An open-label controlled pilot study on 19 patients. 2021 , 9, 955-963	1
544	Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients. 2021 ,	1
543	The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience. 2021 , 67, 101417	

542	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. 2021 , 56, 2964-2974	0
541	A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. 2021 , 23, 1007-1016	0
540	Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial. 2021 , 56, 2948-2955	0
539	Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. 2021 , 27, 686.e1-686.e9	
538	Impact of in Vivo Lymphodepletion on Outcome in Children with Nonmalignant Disorders Receiving Peripheral Blood Stem Cell Transplantation. 2021 , 27, 1020.e1-1020.e1	
537	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. 2021 , 27, 912.e1-912.e6	0
536	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. 2021 , 27, 667.e1-667.e5	0
535	Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia. 2021 , 11, 710545	1
534	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. 2021 , 27, 937.e1-937.e7	2
533	The association of lung function changes with outcomes in children with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. 2021 , 56, 3332-3341	1
532	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. 2021 , 13, 977-987	0
531	Observation of Chronic Graft-Versus-Host Disease Mouse Model Cornea with In Vivo Confocal Microscopy. 2021 , 11,	0
530	Comparison of 2 Different Doses of Antithymocyte Globulin in Conditioning Regimens for Haploidentical Hematopoietic Stem Cell Transplantation. 2021 ,	
529	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. 2021 , 1-9	
528	Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study. 2021 , 27, 663.e1-663.e6	2
527	Production and Application of CAR T Cells: Current and Future Role of Europe. 2021 , 8, 713401	4
526	Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. 2021 , 34, 101305	0
525	Janus Kinase Inhibitors and Cell Therapy. 2021 , 12, 740847	2

524	Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival. 2021 , 21, 598-605	1
523	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. 2021 , 27, 729-737	5
522	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. 2021 , 27, 738-746	2
521	Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL. 2021 , 100, 2773-2785	0
520	[Cutaneous complications following hematopoietic stem cell transplantation]. 2021 , 108, 877-885	
519	First-Line Unrelated Double-Unit Umbilical Cord Blood Transplantation for Acquired Severe Aplastic Anemia. 2021 , 53, 2390-2396	
518	Metabolomic Identification of Alpha-Ketoglutaric Acid Elevation in Pediatric Chronic Graft-versus-Host Disease. 2021 ,	2
517	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. 2021 , 11, 731478	0
516	Mismatch in SIRPB β , a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. 2021 , 5, 3407-3417	0
515	Longitudinal Tear Protein Changes Correlate with Ocular Chronic GVHD Development in Allogeneic Hematopoietic Stem Cell Transplant Patients. 2021 , 11, 8221	0
514	Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival. 2021 , 12, 694843	0
513	Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Patients with Chronic Graft-versus-Host Disease: A First-in-Human Study. 2021 , 13,	2
512	Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies. 2021 , 17, 609-618	0
511	Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). 2021 , 1	1
510	Keeping an 'eye' on ocular GVHD. 2021 , 1-8	0
509	Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study. 2021 , 60, 103243	1
508	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. 2021 , 27, 852.e1-852.e9	
507	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. 2021 , 27, 817-835	5

506	A Scoring System for Predicting the Prognosis of Late-Onset Severe Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 27, 870.e1-870.e7	
505	Oral mucosal graft-versus-host disease and its possibility of antitumor effects. 2022 , 127-150	
504	Graft Versus Host Disease: Management of Acute and Chronic Disease. 2021 , 365-393	
503	Update on ocular graft-versus-host disease. 2021 , 69, 1038-1050	4
502	Pulmonary Complications. 2021 , 543-555	
501	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. 2021 , 106, 508-519	
500	Risk Factors for Ocular Involvement in Pediatric Graft-Versus-Host Disease. 2021 , 40, 1158-1164	0
499	Involvement of ocular surface in graft-versus-host disease: An update from immunopathogenesis to treatment. 2021 , 236, 6190-6199	1
498	Graft-Versus-Host Disease and Late Effects After Hematopoietic Stem Cell Transplantation. 43-51	1
497	Systemic Disease and the Skin. 1-113	15
496	Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. 2020 , 40, 756-772	8
495	Biology and management of chronic graft-versus-host disease. 2009 , 144, 277-98	7
494	Pulmonary Manifestations of Hematological Malignancies: Focus on Pulmonary Chronic Graft-Versus Host Disease. 2015 , 517-527	2
493	Graft vs Host Disease and Skin Manifestations. 2014 , 61-67	1
492	Inflammatory Disorders Affecting the Epidermis of the Vulva. 2015 , 31-69	2
491	Acute Graft-versus-Host Disease. 2008 , 589-620	3
490	Chronic Graft-Versus-Host Disease. 2010 , 577-595	1
489	Treatment of Acute Graft-vs-Host Disease. 2010 , 747-765	2

488	Hepatic Complications of Hematopoietic Cell Transplantation. 2007 , 409-421	5
487	Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications. 2010 , 629, 507-23	2
486	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. 2012 , 303-366	1
485	Acute Graft-Versus-Host Disease. 2019 , 323-330	6
484	Oral Manifestations of Systemic Diseases and their Treatments. 2018 , 1-117	2
483	Graft-Versus-Host Disease (GvHD). 2018 , 221-251	4
482	Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation. 2020 , 625-641	1
481	Allogeneic Transplantation of Hematopoietic Stem Cells. 2012 , 217-235	1
480	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. 2014 , 77-102	1
479	Stamceltransplantatie. 2013 , 161-175	1
478	Ocular Graft-versus-Host Disease. 2011 , 789-796	1
477	Lichenoid and interface dermatitis. 2012 , 219-258	0
476	Skin Signs of Other Systemic Diseases. 2011 , 562-579	2
475	Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1597-1606 ⁴⁷	3
474	Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. 2021 , 56, 596-604	3
473	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. 2020 , 55, 1918-1927	14
472	Clinical severity scores in gastrointestinal graft-versus-host disease. 2014 , 97, 965-71	27
471	The Overlap Syndrome: A Case Report of Chronic Graft-Versus-Host Disease After the Development of a Pseudomembrane. 2021 , 40, 1188-1192	1

470	Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. 2021 , 105, 891-896	8
469	Glycolytic metabolism of pathogenic T cells enables early detection of GvHD by 13C-MRI.	2
468	Narrow-band UVB phototherapy for management of oral chronic graft-versus-host disease. 2015 , 31, 75-82	7
467	Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. 2011 , 2011,	2
466	In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease. 2017 , 2,	5
465	Unique features and clinical importance of acute alloreactive immune responses. 2018 , 3,	6
464	The gut microbiota and graft-versus-host disease. 2019 , 129, 1808-1817	39
463	Cytokine mediators of chronic graft-versus-host disease. 2017 , 127, 2452-2463	55
462	Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 24, 328-340	4
461	Macrophage regulation of graft--host disease. 2020 , 8, 1793-1805	8
460	Oral granuloma in a pediatric patient with chronic graft-versus-host disease: A case report. 2020 , 8, 5663-5669	0
459	Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. 2012 , 7, e44922	19
458	Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. 2013 , 8, e64724	39
457	The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. 2014 , 9, e103254	7
456	Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. 2014 , 9, e107155	8
455	Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. 2015 , 10, e0130026	29
454	Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2r β ⁻ (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation. 2015 , 10, e0133216	8
453	Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country. 2015 , 10, e0137390	7

452	Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. 2016 , 11, e0167997	2
451	Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation. 2017 , 12, e0175337	11
450	Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis. 2020 , 15, e0228451	21
449	Ophthalmic manifestation of leukemia. 2016 , 9, 81-99	3
448	Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. 2016 , 7, 59892-59901	6
447	Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. 2017 , 8, 41590-41604	16
446	Dynamic changes in serum cytokine levels and their clinical significance in predicting acute GVHD. 2017 , 8, 53691-53700	4
445	Evaluation of thromboelastometry parameters as predictive markers for sinusoidal obstruction syndrome in patients undergoing allogeneic stem cell transplantation for acute leukaemia. 2017 , 8, 60001-60014	14
444	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. 2017 , 8, 112972-112979	13
443	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. 2018 , 9, 33528-33535	10
442	Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. 2016 , 7, 32579-91	22
441	A Web-Based Mobile App (INTERACCT App) for Adolescents Undergoing Cancer and Hematopoietic Stem Cell Transplantation Aftercare to Improve the Quality of Medical Information for Clinicians: Observational Study. 2020 , 8, e18781	6
440	Cutaneous manifestations of acute and chronic graft-versus-host disease. 2020 , 155, 76-87	3
439	Challenges in Conducting Studies in Chronic Graft-Host Disease. 2019 , 1, 36-44	2
438	Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. 2020 , 2, 2-4	19
437	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease. 2020 , 18, eAE4799	1
436	The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. 2011 , 108, 732-40	29
435	Outcome of allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission: a single institution study. 2012 , 55, 100-6	3

434	Fulminant gastrointestinal graft-versus-host disease concomitant with cytomegalovirus infection: case report and literature review. 2013 , 19, 597-603	5
433	Esophageal stenosis with sloughing esophagitis: A curious manifestation of graft-vs-host disease. 2015 , 21, 9217-22	13
432	[How I treat chronic graft-versus-host disease]. 2018 , 39, 89-93	1
431	[The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD]. 2020 , 41, 716-722	1
430	Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia. 2012 , 30, 165-72	8
429	Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. 2014 , 29, 630-6	21
428	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. 2015 , 30, 212-8	21
427	Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?. 2020 , 35, 957-969	3
426	Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). 2016 , 7, S21-31	28
425	Ocular graft versus host disease in allogeneic haematopoetic stem cell transplantation in a tertiary care centre in India. 2015 , 142, 543-8	10
424	Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease. 2016 , 7, 509-511	1
423	Kinetics of IFN- γ and IL-17 Production by CD4 and CD8 T Cells during Acute Graft-versus-Host Disease. 2014 , 14, 89-99	10
422	Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation. 2018 , 35, 131-140	11
421	Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study. 2019 , 36, 88-96	3
420	Acute Graft-Versus-Host Disease: A Brief Review. 2020 , 37, 1-4	6
419	Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease. 2019 , 24, e190-e194	4
418	A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials. 2011 , 33, 283-289	6
417	Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations. 2011 , 33, 358-66	3

416	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. 2012 , 34, 109-33	37
415	A fast and fatal course of bronchiectasis: an unusual rare expression of chronic graft versus host disease. A case report. 2016 , 23, 54-59	1
414	Gastroesophageal reflux disease and its association with bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplant recipients. 2013 , 11, 270-3	3
413	Major Pulmonary Complications After Hematopoietic Stem Cell Transplant. 2016 , 14, 259-70	9
412	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 , 18, 599-634	11
411	MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. 2016 , 5, e09394	18
410	Incidence of acute kidney disease after receiving hematopoietic stem cell transplantation: a single-center retrospective study. 2019 , 7, e6467	7
409	Effect of allogeneic stem cell transplantation in patients with minimally differentiated acute myeloid leukemia. 2019 , 8, 50-59	1
408	Treatment of oral chronic graft-versus-host disease: a retrospective cohort study. 2021 , 19, eAO6177	
407	Graft Versus Host Disease. 2021 , 1-23	
406	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. 2021 , 11, 164	6
405	Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease. 2021 , 2, 100409	0
404	Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. 2021 , 12, 761616	5
403	Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. 2021 , 1	0
402	Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. 2021 ,	0
401	Impact of chronic GVHD on QOL assessed by visual analogue scale in pediatric HSCT survivors and differences between raters: a cross-sectional observational study in Japan. 2021 , 1	
400	Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. 2021 ,	6
399	Effectiveness of T-Cell Replete Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/Relapsed B Cell Acute Lymphoblastic Leukemia in Children and Adolescents. 2021 , 9, 743294	1

- 398 Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. **2021**, 1-10 1
- 397 Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. **2021**, 218, 2
- 396 Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. **2021**, 1
- 395 The clinical landscape of chronic graft-versus-host disease management in 2021. **2021**, 1
- 394 Graft versus Host Disease. **2008**, 4821-4830
- 393 Chronic Graft-versus-Host Disease. **2008**, 621-649
- 392 IX ?????????? ?????????? 2008, 120, 175-184
- 391 Hematopoietic Stem Cell Transplantation. **2008**, 501-512 1
- 390 Clinical Aspects of Hematopoietic Stem Cell Transplantation. **2010**, 505-511
- 389 Graft-Versus-Host Disease. **2010**, 433-441
- 388 Gastrointestinal and Hepatic Complications of Solid Organ and Hematopoietic Cell Transplantation. **2010**, 537-555.e6 1
- 387 Acute Toxicities, Late Sequelae, and Quality of Survivorship in Children with Acute Myeloid Leukemia: The Impact of Allogeneic Stem Cell Transplant. **2011**, 265-282
- 386 Chronic Graft Versus Host Disease: Inflammation at the Crossroads of Allo and Auto Immunity. **2011**, 259-280
- 385 Respiratory Symptoms Occurring 4 Months After Allogeneic Hematopoietic Stem Cell Transplantation. **2011**, 707-714
- 384 Progress in chronic graft-versus-host disease. **2011**, 33, 255-6
- 383 Reduced-Intensity and Non-Myeloablative Conditioning Followed by Hematopoietic Cell Transplantation. **2012**, 187-217
- 382 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 381 Hematopoietic Stem Cell Transplantation. **2012**, 3179-3185

- 380 Management of Chronic Graft-versus-Host Disease 2012. **2012**, 1, 37-51 1
- 379 Minimally Invasive Laser-Assisted Biopsy of the Oral Lesions for Oral Graft-Versus-Host Disease after Hematopoietic Stem-Cell Transplantation. **2012**, 37, 147-154
- 378 Graft-Versus-Host Disease. **2013**, 103-131
- 377 Entzündungen des Kolorektums mit bekannter Biologie. **2013**, 533-563
- 376 Hematopoietic stem cell transplantation for malignant diseases. **2013**, 1020-1031
- 375 Oral Complications after Hematopoietic Stem Cell Transplantation. **2013**, 19, 35-47 2
- 374 Mesenchymal Stem Cells as Therapy for Graft Versus Host Disease: What Have We Learned?. **2013**, 173-190
- 373 Hematopoietic Cell Transplantation in Inborn Errors of Metabolism. **2013**, 37-61
- 372 Clinical Significance of Pulmonary Function Tests in Long-Term Survivors after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. **2013**, 03, 6-12
- 371 Graft-Versus-Host Disease (GvHD): Cutaneous Manifestations. **2014**, 255-263
- 370 Gastrointestinal Complications of Hematopoietic Cell Transplantation. 276-285
- 369 Cutaneous Chronic Graft-Versus-Host Disease. 77-105
- 368 Oral Complications in Hematopoietic Stem Cell Transplantation Survivorship. 172-182
- 367 Late Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Bronchiolitis Obliterans Syndrome (BOS) and Organizing Pneumonia (OP). 141-150
- 366 Hepatic Complications of Hematopoietic Stem Cell Transplantation. 286-293
- 365 Graft-Versus-Host Disease. **2014**, 161-171
- 364 Graft Versus Host Disease: From Basics to the Clinic. **2014**, 57-75
- 363 Graft-Versus-Host Disease. **2014**, 425-441

- 362 Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease. 281-294
- 361 Okulde Oberflde nicht infekti. **2014**, 117-180
- 360 Stammzelltransplantation. **2014**, 1461-1466
- 359 A pediatric patient with sclerodermatous chronic graft-versus-host disease that has been responded to imatinib. **2014**, 3, 27-31
- 358 Biomarkers of Graft-Versus-Host Disease. **2014**, 1-23
- 357 ECZEMATOID GRAFT VERSUS HOST DISEASE IN A SEX MISMATCHED ALLOGENEIC STEM CELL TRANSPLANT REFRACTORY TO TREATMENT: A CASE REPORT. **2014**, 3, 3016-3019
- 356 ORAL CHRONIC GRAFT VERSUS HOST DISEASE IN AN IMMUNOCOMPETENT PATIENT: A CASE REPORT. **2014**, 3, 6521-6525
- 355 Hematologic Cancer Survivorship Management: Transplantation. **2015**, 167-186
- 354 Immunomodulation of mesenchymal stem/stromal cells for the onset of cGVHD. **2015**, 35, 233-237
- 353 Hematopoietic Stem Cell Transplant. **2015**, 179-208
- 352 Hematopoietic Stem Cell Transplantation. **2015**, 339-351 1
- 351 Biomarkers of Graft-Versus-Host Disease. **2015**, 1277-1308
- 350 Pumpless extracorporeal interventional lung assist for bronchiolitis obliterans after allogenic peripheral blood stem cell transplantation for acute lymphocytic leukemia. **2015**, 32, 98
- 349 Oral graft vs host disease: An immune system disorder in hematopoietic cell transplantation. **2015**, 4, 96
- 348 Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies. **2015**, 21, 2257-65
- 347 The follow-up, diagnosis, and rehabilitation of patients in late periods following hematopoietic stem cell transplantation: Topical issues. **2015**, 13-18 1
- 346 Immunological and Mucocutaneous Disease. 259-272
- 345 Oral Manifestation of Gastrointestinal Diseases. 2459-2469

- 344 Immunological Disorders: (b) Immunodeficiencies and Gastrointestinal Complications of Organ Transplantation. 2303-2321
- 343 Treatment of refractory chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with low-dose interleukin-2. **2015**, 22, 44-48 1
- 342 A Case of Chronic Graft-versus-host Disease with Symptoms of Masticatory Muscles. **2016**, 29, 155-157
- 341 Specimen Identification Through DNA Analysis. **2016**, 849-864
- 340 Multiple tongue nodules in a patient with chronic graft-versus-host disease. **2016**, 62, 529-533 1
- 339 Graft Versus Host Disease (GVHD). **2016**, 429-449
- 338 Acute and Chronic Graft-Versus-Host Disease of the Skin. **2016**, 101-118
- 337 Introduction to Hematopoietic Cell Transplantation. **2016**, 3-17
- 336 Ocular Graft versus Host Disease: A Review of Clinical Manifestations, Diagnostic Approaches and Treatment. **2016**, 06, 20-33
- 335 Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Genetic Rare Diseases in Children. **2016**, 23, 133-144
- 334 Hematopoietic Stem Cell Transplant in Adolescent and Young Adults With Fanconi Anemia Is Feasible With Acceptable Toxicity, With Those Surviving 100 Days Posttransplant Having Excellent Outcomes. **2016**, 14, 660-664 0
- 333 Diseases with Underlining Internal Conditions. **2017**, 199-220
- 332 Prevention of Acute Graft-Versus-Host Reaction after Allogeneic Unrelated Hematopoietic Stem Cell Transplantation: Comparison of Effectiveness of Treatment Regimens Based on Anti-Thymocyte Globulin and Cyclophosphamide. **2016**, 9, 391-397
- 331 Cutaneous Manifestations of Systemic Disease. **2017**, 421-443
- 330 Cutaneous Graft-Versus-Host Disease. **2017**, 665-683
- 329 Ocular Manifestations of Dermatologic Diseases. **2017**, 197-239
- 328 Sclerodermatous GVHD after Allogeneic Bone Marrow Transplant: a Review. **2017**, 1, 3-11
- 327 Quality and Safety in Hematopoietic Stem Cell Transplant Patients. **2017**, 297-324

- 326 ICU Complications of Hematopoietic Stem Cell Transplantation Including Graft Versus Host Disease. **2017**, 631-640
- 325 Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation. **2017**, 130, 1290-1295
- 324 Blood Marrow Transplantation. **2018**, 47-57
- 323 GRAFT VERSUS HOST DISEASE- ORAL PRESENTATION. **2017**, 4, 4439-4442
- 322 Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. **2018**, 1211-1245
- 321 Pediatric Graft-Versus-Host Disease. **2018**, 155-169
- 320 Skin Diseases Associated with Stem Cell Transplantation. **2018**, 117-137
- 319 Knochenmark. **2018**, 3-38
- 318 History of Hematopoietic Cell Transplantation. **2019**, 413-416
- 317 Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. **2018**, 16, 736-744
- 316 Preventive Use of Azacitidine in Patients with Acute Myeloid Leukemia after Haploidentical Allo-BMT. **2018**, 12, 37-42 1
- 315 Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT. **2018**, 12, 43-50
- 314 Skin, Hair and Musculoskeletal Complications. **2019**, 409-413 1
- 313 The Basic Sequence of Injury in Acute Skin GVHD. **2019**, 35-45
- 312 Mesenchymal Stromal Cells for Graft-Versus-Host Disease. **2019**, 77-88
- 311 Cutaneous Chronic GVHD: Sclerodermatous and Morpheic Variants. **2019**, 69-83
- 310 Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation. **2021**, 55, 68-75
- 309 Systemic Diseases with an Increased Risk of Oral Squamous Cell Carcinoma. **2019**, 119-158

- 308 The Contributions of Pathology to the Diagnosis and Management of GVHD: Caveats and Lessons Learned. **2019**, 1-10
- 307 Klinik. **2019**, 41-66
- 306 Einflussfaktoren auf das Sicca-Syndrom. **2019**, 27-40
- 305 The thoracic air-leak syndrome (TALS): the frequency of occurrence and radiological signs in the structure of late non-infectious lung lesions in children after the allogeneic HSCT. **2019**, 18, 92-102 1
- 304 Adult aplastic anemia patients can maintain remission after allogeneic hematopoietic stem cell transplantation in a mixed chimeric state. **2019**, 4, 729-732
- 303 Extracorporeal Photopheresis in Hematopoietic Cell Transplantation. **2020**, 161-186
- 302 Thoracic Air Leak Syndrome: A Rare and Fatal Complication of Allogeneic Stem Cell Transplant. **2020**, 09, 81-86
- 301 Graft-Versus-Host Disease. **2020**, 551-582
- 300 Graft-Versus-Host Disease and Quality of Life: Can We Make a Difference?. **2020**, 87-96
- 299 History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona. **2020**, 1-11
- 298 [Cutaneous manifestations of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation]. **2020**, 71, 557-568
- 297 OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH ACTIVE DISEASE IN ACUTE MYELOID LEUKEMIA. **2020**, 15, 15
- 296 Data Unit, Translational Research, and Registries. **2022**, 157-165
- 295 Commentary: Ocular surface involvement heralds graft-versus-host disease: Time to act. **2020**, 68, 1562-1563 1
- 294 Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with Hemato-Oncological Diseases. **2020**, 19, 500-508
- 293 Graft Versus Host Disease: Management of Acute and Chronic Disease. **2021**, 1-30
- 292 Ex Vivo Manipulation of Stem Cell Product. **2020**, 1-16
- 291 Lichenoid and Interface Dermatitis. **2020**, 41-92

290 Graft-versus-host disease. **2020**, 114-117.e1

289 Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. **2021**, 0

288 Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. **2021**, 1

287 Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning. **2021**, e14181

286 Skin damage after the hematopoietic stem cell transplantation. Literature review. **2020**, 19, 184-192 1

285 The efficacy of the regimens of graft versus host disease prophylaxis after hematopoietic stem cell transplantation from unrelated donors in children: single center experience. **2020**, 19, 71-82

284 Graft-Versus-Host Disease. **2008**, 439-457

283 Model-based inference of neutralizing antibody avidities against influenza virus.

282 Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study. **2020**, 42, e718-e722 1

281 Polyomavirus, Adenovirus, and Viral Respiratory Diseases. **2021**, 191-219

280 Risk factors associated with severity of dry eye syndrome in ocular graft-versus-host disease. **2020**, 55, 366-372 0

279 Four cases of corneal perforation in patients with chronic graft-versus-host disease. **2011**, 17, 598-606 25

278 Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. **2011**, 17, 2533-43 57

277 Toll-like receptor 2-mediated NF- κ B inflammatory responses in dry eye associated with cGVHD. **2011**, 17, 2605-11 13

276 Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. **2012**, 18, 797-802 42

275 Overview of T-cell depletion in haploidentical stem cell transplantation. **2012**, 10, 264-72 6

274 Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. **2013**, 124, 152-62 2

273 Conjunctival HLA-DR and CD8 expression detected by impression cytology in ocular graft versus host disease. **2013**, 19, 1492-501 11

272	Cardiac effects of chronic graft-versus-host disease after stem cell transplantation. 2013 , 40, 428-34	3
271	Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. 2013 , 8, 351-8	39
270	Esophageal intramucosal hematoma after peripheral blood stem cell transplantation: case report and review of literature. 2014 , 7, 2690-4	
269	The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. 2009 , 7,	
268	Oral manifestations in transplant patients. 2015 , 12, 199-208	7
267	Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation. 2015 , 9, 112-21	5
266	Dry Eye Disease Incidence Associated with Chronic Graft-Host Disease: Nonconcurrent Cohort Study (An American Ophthalmological Society Thesis). 2015 , 113, T11	4
265	Carcinoma of the lip five years after bone marrow transplantation. 2015 , 6, 38	
264	Late Complications in acute Leukemia patients following HSCT: A single center experience. 2016 , 10, 1-6	4
263	Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. 2017 , 42, 452-463	34
262	SupplAzithromycin for Prevention of Graft-Versus-Host Disease: A Randomized Placebo-Controlled Trial. 2018 , 12, 77-83	1
261	Regulatory T Cells and Ocular Graft Versus Host Disease: A Novel Treatment Approach. 2018 , 7, 119-121	
260	[Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation]. 2019 , 40, 404-410	
259	[Progress of chronic graft-versus-host disease]. 2016 , 37, 79-82	0
258	[Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia]. 2019 , 40, 467-471	0
257	[Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation]. 2019 , 40, 713-719	
256	[Study on the correlation between CMV reactivation and bronchiolitis obliteans after allogeneic hematopoietic stem cell transplantation]. 2015 , 36, 389-92	1
255	[The comparison of predicting clinical outcomes between immunophenotype and hematological complete remission before human leukocyte antigen-matched sibling donor transplantation in acute myeloid leukemia]. 2018 , 39, 617-623	0

- 254 [A clinical study of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric patients with acquired severe aplastic anemia: single center experience]. **2019**, 40, 301-305 0
- 253 [Comparison of haploidentical hematopoietic stem cell transplantation and matched-sibling donor transplantation for the treatment of paroxysmal nocturnal hemoglobinuria]. **2019**, 40, 306-311
- 252 [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation]. **2016**, 37, 138-43 1
- 251 [How I treat acute graft versus host disease]. **2017**, 38, 649-655 0
- 250 [Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation]. **2020**, 41, 106-111 0
- 249 [Impact of splenomegaly on outcomes of allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia]. **2020**, 41, 308-312
- 248 [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor- β receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT]. **2020**, 41, 743-748
- 247 Comparison of microtransplantation, chemotherapy and allogeneic transplantation in post-remission therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia. **2020**, 10, 3852-3866 1
- 246 Follicular Graft Vs Host Reaction: A Rare Presentation. **2020**, 11, 988-990
- 245 [Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)]. **2021**, 42, 265-275
- 244 Outcome of haploidentical peripheral blood allografts utilizing post-transplant cyclophosphamide compared to matched sibling and unrelated donor bone marrow allografts in pediatric patients with hematological malignancies: A single center analysis. **2021**, 0
- 243 Risk Factors for Graft-Versus-Host Disease and Survival in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience. **2021**,
- 242 Antithymocyte globulin exposure in CD34+ T-cell depleted allogeneic hematopoietic cell transplantation. **2021**, 0
- 241 Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients. **2021**,
- 240 Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. **2021**, 2
- 239 Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I. **2021**, 2
- 238 Follicular graft Vs host reaction: A rare presentation. **2020**, 11, 988
- 237 Hepatic Variant of Graft-vs-Host Disease.. **2022**,

- 236 Graft-versus-host-disease (GVHD)(engl. graft-versus-host disease). **2021**, 229-239
- 235 Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.. **2021**, 11, 805514 2
- 234 Risk Factors of Graft-Versus-Host Disease in the Iranian Allogeneic Hematopoietic Stem Cell Transplantation: A 10-Year Experience.. **2021**, 35, 145 0
- 233 Preemptive Interferon- γ Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.. **2022**, 13, 757002 1
- 232 Comparable Outcomes and Health-Related Quality of Life for Severe Aplastic Anemia: Haploidentical Combined With a Single Cord Blood Unit Matched Related Transplants.. **2021**, 11, 714033 0
- 231 Benefits of Newborn Screening and Hematopoietic Cell Transplant in Infantile Krabbe Disease.. **2022**, 1
- 230 Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.. **2022**, 0
- 229 A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.. **2022**, 101, 869
- 228 Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.. **2022**, 115, 534 1
- 227 Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft--host disease after haploidentical allogeneic hematopoietic stem cell transplantation.. **2022**, 13, 20406207211072838 2
- 226 To Lighten the Burden of Cure: Thyroid Disease in Long-Term Survivors After TBI Conditioning for Paediatric ALL.. **2021**, 9, 798974 1
- 225 Oral Graft-Versus-Host Disease. **2022**, 213-225
- 224 Quality of Life of Sickle Cell Disease Patients After Hematopoietic Stem Cell Transplantation: a Longitudinal Study. 1
- 223 Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.. **2021**, 11, 773394 1
- 222 Model-based inference of neutralizing antibody avidities against influenza virus.. **2022**, 18, e1010243 0
- 221 Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis.. **2022**, 3
- 220 Ocular graft-versus-host disease and dry eye disease after paediatric haematopoietic stem cell transplantation - incidence and risk factors.. **2022**, 1
- 219 Functional Improvement During Prolonged Hospitalization in a Patient With Acute Myeloid Leukemia Utilizing Physical and Occupational Therapy Comanagement. **2022**, Publish Ahead of Print,

218	Poor Outcome After Hematopoietic Stem Cell Transplantation Of Patients With Unclassified Inherited Bone Marrow Failure Syndromes.. 2021 ,	
217	Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases.. 2022 , 31, 9636897211070238	
216	Outcomes following DLI in patients with haematological malignancies: Donor characteristics matter.. 2022 ,	
215	HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.. 2022 , 115, 406	
214	Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study.. 2021 , 11, 792142	0
213	Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. 2022 ,	1
212	Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease.. 2022 , 25, 103592	2
211	Established and Emerging Treatments of Skin GvHD.. 2022 , 13, 838494	
210	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis.. 2022 ,	
209	Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.. 2022 , 9, e111-e120	2
208	Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial.. 2022 ,	0
207	Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation.. 2022 ,	1
206	Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.. 2022 , 168, 19-39	0
205	Neurologic complications in the treatment of childhood malignancies. 2022 , 433-462	
204	Tear Cytokines as Biomarkers for Acute Ocular Graft-Versus-Host Disease.. 2022 ,	
203	Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.. 2022 , 12, 801879	0
202	Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.. 2022 , 115, 525	0
201	How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?. 2022 , 103405	0

- 200 Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures.. **2022**, 14, eabg3083 1
- 199 Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.. **2022**, 10, 808103 1
- 198 Airway disease in hematologic malignancies.. **2022**, 1-11 0
- 197 Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.. **2022**, 0
- 196 The impact of transportation time on apoptosis in allogeneic stem cell grafts and the clinical outcome in malignant patients with unrelated donors.. **2022**, 0
- 195 Outcomes and complications of cataract surgery in patients with chronic ocular graft-versus-host-disease-a multicenter, retrospective analysis.. **2022**, 1 0
- 194 Non-infectious pulmonary toxicity after allogeneic hematopoietic cell transplantation.. **2022**, 1
- 193 Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study.. **2022**, 22, 292 1
- 192 Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study.. **2022**, 2
- 191 Aggressive Cutaneous Squamous Cell Carcinomas Following Treatment for Graft-versus-Host Disease: A Case Report and Review of Risk Factors.. **2022**, 9, 122-130 0
- 190 Non-Invasive Diagnosis of Pediatric Intestinal Graft-Versus-Host Disease: A Case Series. **2022**, 3, 115-123 0
- 189 Oral health status after hematopoietic stem cell transplantations: Outcomes from an adult Italian population.. **2022**, 0
- 188 Allogeneic Hematopoietic Stem Cell Transplantation For Heavily Pretreated Patients With Mycosis Fungoides and Sezary Syndrome.. **2022**, e15447 0
- 187 Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.. **2022**, 0
- 186 Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide.. **2021**, 0
- 185 Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.. **2022**, 1 0
- 184 Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.. **2021**, 0
- 183 Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.. **2022**, 0

- 182 Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.. **2022**, 1-9
- 181 Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.. **2022**, 70, 103343 1
- 180 Diagnosis and staging of ophthalmic manifestations of the graft-versus-host reaction after allogeneic hematopoietic stem cell transplantation. **2021**, 14, 91-102 1
- 179 Post-Hematopoietic Stem Cell Transplantation Immune-Mediated Anemia: A Literature Review and Novel Therapeutics.. **2021**, 2
- 178 Case Report: Graft Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.. **2021**, 11, 749691
- 177 A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.. **2021**, 9, 774853
- 176 Late follow-up of genital and ophthalmologic chronic graft-versus-host disease in females after allogeneic stem cell transplantation.. **2021**, 0
- 175 Extracorporeal photopheresis in chronic graft-versus-host disease: clinical description and economic study.. **2021**,
- 174 Updates in chronic graft-versus-host disease. **2021**, 2021, 648-654 1
- 173 Value of Autoantibody Expression During Long-Term Follow-Up in Paediatric ALL Patients After Allogeneic Haematopoietic Stem Cell Transplantation.. **2021**, 9, 788360
- 172 Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.. **2022**, 1
- 171 In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach. **2022**, 46, 1
- 170 Tear Film Immunological Profile in Patients with Ocular Graft versus Host Disease.. **2022**, 1-9 0
- 169 Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.. **2022**, 0
- 168 The Relevance of Skin Biopsies in General Internal Medicine: Facts and Myths.. **2022**, 1
- 167 Bone Marrow Grafts From Pediatric Donors May Contain A Considerable Number of Hematogones. 1
- 166 Early reconstitution of lymphocytes after allo-HSCT affects chronic GVHD.
- 165 Composite tissue allotransplantation. 313-319

164 Data_Sheet_1.pdf. **2020**,

163 Table_1.DOCX. **2019**,

162 Presentation_1.pptx. **2018**,

161 Data_Sheet_1.zip. **2020**,

160 Data_Sheet_1.docx. **2019**,

159 Table_1.xls. **2019**,

158 Table_2.docx. **2019**,

157 Table_1.DOC. **2020**,

156 Table_2.DOC. **2020**,

155 Table_3.DOC. **2020**,

154 Table_4.DOC. **2020**,

153 Table_1.docx. **2019**,

152 Table_2.docx. **2019**,

151 Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults with CML in the TKI Era.. **2022**,

0

150 Graft Versus Host Disease. **2022**, 7557-7579

149 IL-6 Responsiveness of CD4 and CD8 T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy.. **2022**, 11,

148 The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. **2022**, 13,

0

147 Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series.. **2022**,

1

- 146 Ocular Graft-versus-Host Disease Underdiagnosis: A Survey Study.. **2022**, 16, 1419-1426
- 145 Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.. **2022**,
- 144 Autoimmune diseases after allogeneic stem cell transplantation: a clinician's guide and future outlook.. **2022**,
- 143 -Evaluating differential expression of fibrosis-related genes and their correlation with blood vessel density in chronic cutaneous graft-versus-host disease. **2022**,
- 142 Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.. **2022**, ○
- 141 PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome.. **2022**, 13, 879501 ○
- 140 Skin Signs of Other Systemic Diseases. **2016**, 573-591.e6 2
- 139 Oral Chronic Graft-Versus-Host Disease. **2022**, 3,
- 138 Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia. 2
- 137 Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. **2022**, 1
- 136 Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. **2022**, 6, e730
- 135 A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan + clofarabine in allogeneic stem cell transplantation.
- 134 Tongue graft-versus-host disease: remission with ruxolitinib. **2022**, 15, e247888
- 133 Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation. **2022**, ○
- 132 Haematopoietic Cell Transplantation. **2022**, 531-542
- 131 Transplantation Pathology. **2022**, 353-403
- 130 Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing. **2022**, 31, 096368972211029 ○
- 129 Graft-Versus-Host Disease: Pathogenesis and Treatment.

- 128 T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCR $\alpha\beta$ /CD19+ Depletion Platforms. 12, ○
- 127 The Importance of Secretor-Status in Norovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation. **2022**, 14, 1350
- 126 J-SUPPORT research policy for oral mucositis associated with cancer treatment.
- 125 Clinical features, treatment and outcome of pediatric steroid refractory acute Graft-versus-Host disease: a multicenter study. **2022**,
- 124 Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. ○
- 123 Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States. **2022**, 25, 857-863
- 122 Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. 1
- 121 Impact of allogeneic stem cell transplantation in childhood and adolescence on quality of adulthood life: A case-control study.
- 120 Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents. **2022**, 2022,
- 119 Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study. 13,
- 118 Late pulmonary complications related to cancer treatment in children. ○
- 117 Pediatric Graft-Versus-Host Disease. **2022**,
- 116 Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation.
- 115 Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). ○
- 114 Mapping research trends of chronic ocular graft-versus-host disease from 2009 to 2020: a bibliometric analysis. ○
- 113 Busulfan (Bu) and Cyclophosphamide (Cy) based conditioning regimen still holds the promise of being a safe and efficacious regimen for Allogeneic Transplantation in patients with Transfusion Dependent Thalassemia (TDT), even in high risk.
- 112 Extracorporeal photopheresis for the treatment of chronic graft versus host disease. **2022**, 27, 785-794
- 111 Tear Cytokines Associated With Therapeutic Effects in Chronic Ocular Graft-Versus-Host Disease. **2022**, Publish Ahead of Print, ○

110	Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand. 2022,	
109	Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. 2022,	0
108	Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience. 2022, 120, 106918	0
107	Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.	0
106	Characterization of Hepatic Dysfunction in subjects diagnosed with Chronic GVHD by NIH Consensus Criteria. 2022,	0
105	Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease.	0
104	Biomarkers in Ocular Graft-Versus-Host Disease: Implications for the Involvement of B Cells. 2022,	1
103	Desiccating-stress significantly increases the risk for chronic ocular Graft-versus-Host-Disease Short Titel: Desiccating-stress increases risk of ocular GVHD. 2022,	0
102	Ocular Chronic Graft-Versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes After Allogeneic Haematopoietic Cell Transplantation. 2022,	
101	Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. 13,	0
100	Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia. 2022, 22,	1
99	Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy. 2022,	0
98	Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review. 2022, 62,	0
97	Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation. 2022, 12,	
96	Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. 2022, 6, 4491-4500	1
95	Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. 1-5	
94	Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease. 2022,	0
93	Clinical Outcomes after One-day or Two-day Intervals in Conditioning Regimens for allo-HCT. Publish Ahead of Print,	0

- 92 Multicenter prospective validation study for international chronic ocular graft-versus-host disease consensus diagnostic criteria. **2022**, 26, 200-208 ○
- 91 Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients: A systematic review and meta-analysis. **2022**, 101, e29160 ○
- 90 Karnofsky performance status and visual analogue scale scores are simple indicators for quality of life in long-term AYA survivors who received allogeneic hematopoietic stem cells transplantation in childhood. ○
- 89 Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. ○
- 88 T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia. 13, ○
- 87 Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: Importance of Graft Source. ○
- 86 Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. ○
- 85 Meibomian gland dysfunction: a route of ocular graft-versus-host disease progression that drives a vicious cycle of ocular surface inflammatory damage. **2022**, ○
- 84 Enasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies. 1
- 83 Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York. **2022**, 69, ○
- 82 Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD. **2022**, 15, 1100 ○
- 81 American Society for Transplantation and Cellular Therapy Return to Work Guidance Committee Recommendations for Health Care Providers Who Take Care of Hematopoietic Cell Transplant Patients. **2022**, ○
- 80 Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents. **2022**, 2022, ○
- 79 Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer. **2022**, 36, 2705-2714 ○
- 78 Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation. ○
- 77 Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort study. **2022**, ○
- 76 Respiratory Complications. 1-37 ○
- 75 Chronic gvhd dictionary Eurograft cost action initiative consensus report. ○

- 74 Implementation of Routine Endoscopy with Narrow Band Imaging in the Evaluation of Oral and Upper Airways Lesions in Oral Chronic Graft-Versus-Host Disease: A Preliminary Study. **2022**, 12, 1628 ○
- 73 Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study. **2022**, 54, 2617-2626 ○
- 72 Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment. ○
- 71 Relationship between Iron deposition and T lymphocytes in children with β -thalassemia with haematopoietic stem cell transplantation. 10, ○
- 70 Rheumatological manifestations of chronic graft versus host disease - Case series. **2023**, 98, 102709 ○
- 69 Cutaneous localisation of Hodgkin lymphoma resembling hard-to-heal graft-versus-host disease skin ulcers: a tricky mimic. **2022**, 31, 1011-1012 ○
- 68 Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. 13, ○
- 67 Musculoskeletal Chronic Graft versus Host Disease: A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. **2022**, 29, 8415-8430 ○
- 66 Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia. ○
- 65 The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease. ○
- 64 Structure-based design, drug-likeness, and pharmacokinetic studies of novel substituted pyrimidine derivatives as potent HCV NS3/A4 protease inhibitors. **2022**, 46, 102539 ○
- 63 The ocular graft-versus-host disease: the path from current knowledge to future managements. ○
- 62 Allogeneic Hematopoietic Cell Transplantation After CAR T-cell Therapy in Large B-cell Lymphoma. **2022**, ○
- 61 Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study. 12, ○
- 60 Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. **2022**, 14, 5670 ○
- 59 Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy. **2022**, ○
- 58 Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation. **2022**, 17, ○
- 57 A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. 1-11 ○

- 56 First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens. ○
- 55 EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. ○
- 54 The influence of social constraints on the quality of life of hematopoietic stem cell transplantation survivors: The chain mediating effect of illness perceptions and the fear of cancer recurrence. 13, ○
- 53 Pre-transplantation vitamin D deficiency increases acute graft-versus-host disease after hematopoietic stem cell transplantation in thalassemia major patients. ○
- 52 Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. ○
- 51 Effect of CD34+ cell dose on the outcomes of allogeneic stem cell transplantation with post-transplant cyclophosphamide. **2022**, ○
- 50 Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. ○
- 49 Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol. **2022**, 12, e065676 ○
- 48 Okulde Graft-Versus-Host Erkrankung. ○
- 47 Inferences for current chronic graft-versus-host-disease free and relapse free survival. **2022**, 22, ○
- 46 Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anaemia in Children and Young Adults: A Report from the Pediatric.... **2022**, ○
- 45 Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignancies. 12, ○
- 44 Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: The Importance of Graft Source. **2022**, ○
- 43 Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation. ○
- 42 Three Cases Improved by Dental Interventions for Cosmetic Disturbance and Dysfunction in the Oral and Maxillofacial Region Caused after Treatment of Hematologic Malignancies. **2022**, 28, 12-19 ○
- 41 Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. **2023**, ○
- 40 Prognostic impact of the simple L-index and absolute lymphocyte count early after allogeneic hematopoietic stem cell transplantation. **2023**, ○
- 39 Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival. **2023**, ○

- 38 Age-Related Differences in the Clinical Patterns of Ocular Graft-Versus-Host Disease. **2022**, 52, 366-373 ○
- 37 Enfermedad injerto contra receptor crónica: revisión sistemática de la afectación articular y fascial. **2023**, ○
- 36 A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors. **2023**, 23, ○
- 35 Insights and strategies to promote immune tolerance in allogeneic hematopoietic stem cell transplantation recipients. **2023**, 329-360 ○
- 34 Novel pre-clinical mouse models for chronic Graft-versus-Host Disease. 13, ○
- 33 Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI. ○
- 32 Non-Neoplastic and Inflammatory Disorders of the Small Bowel. **2024**, 119-150 ○
- 31 More than two courses of consolidation therapy pre-transplantation benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Publish Ahead of Print, ○
- 30 Chronic graft-versus-host disease in pediatric patients: Differences and challenges. **2023**, 101054 ○
- 29 Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. ○
- 28 Oral complications in a paediatric graft versus host disease (GVHD) clinic: A retrospective study. ○
- 27 Elevated ADA2 Enzyme Activity at the Onset of Chronic Graft-versus-Host Disease in Children. **2023**, ○
- 26 Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease. 10, ○
- 25 Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. **2023**, 4, 22-37 ○
- 24 Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. ○
- 23 Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. **2023**, 127, 107052 ○
- 22 Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion. ○
- 21 Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial. **2023**, ○

- 20 Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy. **2023**, ○
- 19 Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis. ○
- 18 Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease. **2023**, 159, 393 ○
- 17 Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients. **2023**, 6, e202201786 ○
- 16 Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease. **2023**, 18, e0282753 ○
- 15 Pharmacoinformatics-based strategy in designing and profiling of some Pyrazole analogues as novel hepatitis C virus inhibitors with pharmacokinetic analysis. **2023**, 10, 240-254 ○
- 14 Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study. **2023**, 11, 742 ○
- 13 Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). 11, ○
- 12 Blockade of CD122 on memory T cells in the skin suppresses sclerodermatous graft-versus-host disease. **2023**, 109, 127-135 ○
- 11 Adverse impact of a high CD4 / CD8 ratio in the allograft may be overcome by methotrexate- but not mycophenolate- or post-transplant cyclophosphamide-based graft versus host disease prophylaxis. ○
- 10 The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation. **2023**, 29, 75-83 ○
- 9 Positive Newborn Screening for Severe Combined Immunodeficiency: What Should the Pediatrician Do?. **2023**, 17, 117955652311628 ○
- 8 Is Old (Fludrabine/Busulfan/Cyclophosphamide/rAntiThymocyteGlobulin) Conditioning Still Gold for Allogeneic Transplants in Transfusion Dependent Beta-Thalassemia of All Risk Categories in 21st Century?. ○
- 7 Pulmonary Manifestations of Hematological Malignancies. **2023**, 705-714 ○
- 6 Graft-Versus-Host Disease (GvHD). **2023**, 241-267 ○
- 5 Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ○
- 4 A French single center experience on allogeneic stem cell transplant cryopreservation during SARS-CoV2 pandemic.. **2023**, ○
- 3 Multi-parametric MRI in the diagnosis and scoring of gastrointestinal acute graft-versus-host disease. ○

- 2 Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. **2023**, 18, e0284476 ○
- 1 Chronic graft-versus-recipient disease: Systematic review of joint and fascial involvement. **2023**, ○